ATE531812T1 - Humanisierung von nager-antikörpern - Google Patents

Humanisierung von nager-antikörpern

Info

Publication number: ATE531812T1
Authority: AT; Austria
Prior art keywords: antibody; humanization; rodent antibodies; complementarity determining; determining region
Prior art date: 1997-12-05

Application number

AT98960758T

Other languages

English (en)

Inventor

Carlos Barbas

Christoph Rader

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-05

Filing date

1998-12-04

Publication date

2011-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25532007&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE531812(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-12-04 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE531812T1 publication Critical patent/ATE531812T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT98960758T 1997-12-05 1998-12-04 Humanisierung von nager-antikörpern ATE531812T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98601697A	1997-12-05	1997-12-05
PCT/US1998/025828 WO1999029888A1 (en)	1997-12-05	1998-12-04	Humanization of murine antibody

Publications (1)

Publication Number	Publication Date
ATE531812T1 true ATE531812T1 (de)	2011-11-15

Family

ID=25532007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98960758T ATE531812T1 (de)	1997-12-05	1998-12-04	Humanisierung von nager-antikörpern

Country Status (13)

Country	Link
US (1)	US7087409B2 (de)
EP (1)	EP1034298B1 (de)
JP (1)	JP4460155B2 (de)
AT (1)	ATE531812T1 (de)
AU (1)	AU760562B2 (de)
BR (1)	BR9813365A (de)
CA (1)	CA2312208C (de)
CY (1)	CY1112365T1 (de)
DK (1)	DK1034298T3 (de)
ES (1)	ES2375931T3 (de)
IL (2)	IL136544A0 (de)
PT (1)	PT1034298E (de)
WO (1)	WO1999029888A1 (de)

Families Citing this family (1056)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1141286T3 (da)	1998-12-14	2007-02-19	Genetics Inst Llc	Kæde af cytokinreceptorer
US7553487B2 (en)	1998-12-14	2009-06-30	Genetics Institute, Llc	Method and compositions for treating asthma
EP1436329A4 (de) *	2001-09-20	2005-04-27	Alexion Pharma Inc	Anti-pdgf-antikörper und verfahren zur herstellung konstruierter antikörper
CA2536238C (en) *	2003-08-18	2015-04-07	Medimmune, Inc.	Humanization of antibodies
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
TWI333977B (en)	2003-09-18	2010-12-01	Symphogen As	Method for linking sequences of interest
US7981843B2 (en) *	2004-01-20	2011-07-19	Kalobios Pharmaceuticals, Inc.	Antibody specificity transfer using minimal essential binding determinants
US7794713B2 (en)	2004-04-07	2010-09-14	Lpath, Inc.	Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20090098142A1 (en) *	2004-06-09	2009-04-16	Kasaian Marion T	Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
DK3540062T3 (da)	2004-11-16	2021-06-28	Humanigen Inc	Immunoglobulin-variabel region kassetteudskiftning
US7862812B2 (en)	2006-05-31	2011-01-04	Lpath, Inc.	Methods for decreasing immune response and treating immune conditions
US7829674B2 (en)	2006-10-27	2010-11-09	Lpath, Inc.	Compositions and methods for binding sphingosine-1-phosphate
AU2007313822A1 (en)	2006-10-27	2008-05-08	Lpath, Inc.	Compositions and methods for treating ocular diseases and conditions
CN101622346A (zh) *	2007-03-01	2010-01-06	西福根有限公司	克隆关联抗体的方法
DK2132573T3 (da)	2007-03-02	2014-07-14	Genentech Inc	Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression
CN101977935A (zh) *	2007-04-23	2011-02-16	惠氏公司	用于治疗和监测il-13相关病症的方法和组合物
JP5989299B2 (ja)	2007-05-30	2016-09-07	エルパス・インコーポレイテッドＬｐａｔｈ，Ｉｎｃ．	リゾホスファチジン酸結合のための組成物と方法
US20110064744A1 (en) *	2007-05-30	2011-03-17	Sabbadini Roger A	Prevention and treatment of pain using antibodies to lysophosphatidic acid
US20090304719A1 (en)	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
SG193868A1 (en)	2007-09-26	2013-10-30	Chugai Pharmaceutical Co Ltd	Modified antibody constant region
US20090087443A1 (en) *	2007-09-27	2009-04-02	Bartels Stephen P	Pharmacological Adjunctive Treatment Associated with Glaucoma Filtration Surgery
US8361465B2 (en) *	2007-10-26	2013-01-29	Lpath, Inc.	Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
AU2008323811B8 (en)	2007-11-08	2014-09-18	Precision Biologics, Inc.	Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
TWI468417B (zh)	2007-11-30	2015-01-11	Genentech Inc	抗－ｖｅｇｆ抗體
AU2009305113B2 (en)	2008-10-13	2015-07-16	Institute For Research In Biomedicine	Dengue virus neutralizing antibodies and uses thereof
KR101834999B1 (ko)	2008-10-14	2018-03-06	제넨테크, 인크.	이뮤노글로불린 변이체 및 그의 용도
US8871202B2 (en)	2008-10-24	2014-10-28	Lpath, Inc.	Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AR074369A1 (es) *	2008-11-20	2011-01-12	Genentech Inc	Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
WO2010062960A2 (en)	2008-11-26	2010-06-03	Cedars-Sinai Medical Center	METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US8401799B2 (en) *	2008-12-05	2013-03-19	Lpath, Inc.	Antibody design using anti-lipid antibody crystal structures
WO2010065921A2 (en) *	2008-12-05	2010-06-10	Lpath, Inc.	Antibody design using anti-lipid antibody crystal structures
NZ717213A (en)	2008-12-09	2017-10-27	Genentech Inc	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
KR101812811B1 (ko)	2008-12-23	2017-12-27	제넨테크, 인크.	단백질 ａ에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체
JP5851842B2 (ja)	2009-01-12	2016-02-03	サイトムエックスセラピューティクス, インク.CytomX Therapeutics, Inc.	改変した抗体組成物、それを作製および使用する方法
US8399219B2 (en) *	2009-02-23	2013-03-19	Cytomx Therapeutics, Inc.	Protease activatable interferon alpha proprotein
US20100292443A1 (en) *	2009-02-26	2010-11-18	Sabbadini Roger A	Humanized platelet activating factor antibody design using anti-lipid antibody templates
AR075925A1 (es)	2009-03-25	2011-05-04	Genentech Inc	Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos
US20100297127A1 (en)	2009-04-08	2010-11-25	Ghilardi Nico P	Use of il-27 antagonists to treat lupus
WO2010121093A2 (en) *	2009-04-17	2010-10-21	Lpath, Inc.	Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2010146059A2 (en)	2009-06-16	2010-12-23	F. Hoffmann-La Roche Ag	Biomarkers for igf-1r inhibitor therapy
WO2011006001A1 (en)	2009-07-09	2011-01-13	Genentech, Inc.	Animal model for the evaluation of adjuvant therapies of cancer
BR112012000735A2 (pt)	2009-07-13	2016-11-16	Genentech Inc	"métodos, kits e conjuntos de compostos"
WO2011014457A1 (en)	2009-07-27	2011-02-03	Genentech, Inc.	Combination treatments
SG178177A1 (en)	2009-07-31	2012-03-29	Genentech Inc	Inhibition of tumor metastasis using bv8- or g-csf-antagonists
AU2010282733B2 (en)	2009-08-11	2016-07-14	Genentech, Inc.	Production of proteins in glutamine-free cell culture media
WO2011020049A1 (en)	2009-08-14	2011-02-17	Genentech, Inc.	Biological markers for monitoring patient response to vegf antagonists
US9321823B2 (en)	2009-09-02	2016-04-26	Genentech, Inc.	Mutant smoothened and methods of using the same
US20110064670A1 (en)	2009-09-11	2011-03-17	Genentech, Inc.	Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
EP2478114B1 (de)	2009-09-17	2014-12-17	F.Hoffmann-La Roche Ag	Verfahren zur lung krebsdiagnostik
MA33973B1 (fr)	2009-09-30	2013-02-01	Genentech Inc	Méthodes de traitement du cancer à l'aide d'antagonistes de notch
WO2011060015A1 (en)	2009-11-11	2011-05-19	Genentech, Inc.	Methods and compositions for detecting target proteins
ES2565208T3 (es)	2009-12-11	2016-04-01	F. Hoffmann-La Roche Ag	Anticuerpos anti-VEGF-C y métodos de uso de los mismos
RU2609658C2 (ru)	2009-12-21	2017-02-02	Дженентек, Инк.	Состав, содержащий антитело
TW201130971A (en)	2009-12-23	2011-09-16	Genentech Inc	Anti-Bv8 antibodies and uses thereof
WO2011092593A2 (en)	2010-01-20	2011-08-04	Institute For Research In Biomedicine	Hiv-1 neutralizing antibodies and uses thereof
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
WO2011106723A2 (en) *	2010-02-26	2011-09-01	Lpath, Inc.	Anti-paf antibodies
RU2587625C2 (ru)	2010-03-24	2016-06-20	Дженентек, Инк.	Анти-lrp6 антитела
WO2011133931A1 (en)	2010-04-22	2011-10-27	Genentech, Inc.	Use of il-27 antagonists for treating inflammatory bowel disease
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
WO2011153224A2 (en)	2010-06-02	2011-12-08	Genentech, Inc.	Diagnostic methods and compositions for treatment of cancer
KR101885388B1 (ko)	2010-06-18	2018-08-03	제넨테크, 인크.	항-Ａｘｌ 항체 및 사용 방법
WO2011161189A1 (en)	2010-06-24	2011-12-29	F. Hoffmann-La Roche Ag	Anti-hepsin antibodies and methods of use
CN103097418A (zh)	2010-07-09	2013-05-08	霍夫曼-拉罗奇有限公司	抗神经毡蛋白抗体及使用方法
JP2013534307A (ja)	2010-07-19	2013-09-02	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	抗癌治療への応答可能性の増大した患者を同定する方法
EP2848940A1 (de)	2010-07-19	2015-03-18	F. Hoffmann-La Roche AG	Verfahren zur Identifizierung eines Patienten mit erhöhter Wahrscheinlichkeit des Ansprechens auf eine Antitumortherapie
WO2012010582A1 (en)	2010-07-21	2012-01-26	Roche Glycart Ag	Anti-cxcr5 antibodies and methods of use
BR112013002535A2 (pt)	2010-08-03	2019-09-24	F. Hoffmann - La Roche Ag	biomarcadores de leucemia linfocítica crônica (cll)
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
CA2805564A1 (en)	2010-08-05	2012-02-09	Stefan Jenewein	Anti-mhc antibody anti-viral cytokine fusion protein
KR101653030B1 (ko)	2010-08-13	2016-08-31	로슈 글리카트 아게	항-테나신-c a２ 항체 및 이의 사용 방법
EA034742B1 (ru)	2010-08-13	2020-03-16	Роше Гликарт Аг	Антитела к fap, полинуклеотид, вектор и клетка для их получения и их применения
MX2013001267A (es)	2010-08-13	2013-04-10	Genentech Inc	ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
SG10201506782XA (en)	2010-08-27	2015-10-29	Stem Centrx Inc	Notum protein modulators and methods of use
JP2013537966A (ja)	2010-08-31	2013-10-07	ジェネンテック，インコーポレイテッド	バイオマーカー及び治療の方法
WO2012031273A2 (en)	2010-09-03	2012-03-08	Stem Centrx, Inc.	Novel modulators and methods of use
JP5974012B2 (ja)	2010-10-05	2016-08-23	ジェネンテック，インコーポレイテッド	突然変異体スムースンド及びその使用方法
EA201390669A1 (ru)	2010-11-10	2013-11-29	Дженентек, Инк.	Способы и композиции для иммунотерапии заболеваний нервной системы
SG10201601792UA (en)	2010-12-08	2016-04-28	Stemcentrx Inc	Novel modulators and methods of use
KR101615420B1 (ko)	2010-12-16	2016-04-26	제넨테크, 인크.	Th2 억제에 관한 진단 및 치료
MA34881B1 (fr)	2010-12-20	2014-02-01	Genentech Inc	Anticorps et immunoconjugués anti-mésothéline
JP2014511106A (ja)	2010-12-22	2014-05-08	ジェネンテック，インコーポレイテッド	抗ｐｃｓｋ９抗体及び使用方法
BR112013014644A2 (pt)	2011-01-03	2017-03-07	F Hoffmann - La Roche Ag	composição farmacêutica e complexo
LT3075745T (lt)	2011-02-10	2018-11-26	Roche Glycart Ag	Mutavę interleukino-2 polipeptidai
MX2013009151A (es)	2011-02-10	2013-08-29	Roche Glycart Ag	Inmunoterapia mejorada.
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
WO2012125569A2 (en)	2011-03-11	2012-09-20	Beth Israel Deaconess Medical Center, Inc.	Anti-cd40 antibodies and uses thereof
HUE041335T2 (hu)	2011-03-29	2019-05-28	Roche Glycart Ag	Antitest FC-variánsok
JP2014516511A (ja)	2011-04-07	2014-07-17	ジェネンテック，インコーポレイテッド	抗ｆｇｆｒ４抗体及び使用方法
EA201892619A1 (ru)	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2833212C (en)	2011-05-12	2020-06-09	Genentech, Inc.	Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
TWI547500B (zh)	2011-05-16	2016-09-01	建南德克公司	Ｆｇｆｒ１促效劑及其使用方法
JP6400470B2 (ja)	2011-05-16	2018-10-03	ジェネロン（シャンハイ）コーポレイションリミテッド	多重特異性Ｆａｂ融合タンパク質および使用法
CA2837914A1 (en)	2011-06-15	2012-12-20	F. Hoffmann-La Roche Ag	Anti-human epo receptor antibodies and methods of use
US20130004484A1 (en)	2011-06-30	2013-01-03	Genentech, Inc.	Anti-c-met antibody formulations
JP2013040160A (ja)	2011-07-01	2013-02-28	Genentech Inc	自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
WO2013019906A1 (en)	2011-08-01	2013-02-07	Genentech, Inc.	Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
MX2014001736A (es)	2011-08-17	2014-03-31	Genentech Inc	Inhibicion de angiogenesis en tumores refractarios.
US20140363438A1 (en)	2011-08-17	2014-12-11	Genentech, Inc.	Neuregulin antibodies and uses thereof
ES2659764T3 (es)	2011-08-23	2018-03-19	Roche Glycart Ag	Moléculas biespecíficas de unión a antígeno activadoras de linfocitos T
HUE039703T2 (hu)	2011-08-23	2019-01-28	Roche Glycart Ag	Bispecifikus antigénkötõ molekulák
BR112014004168A2 (pt)	2011-08-23	2017-12-12	Roche Glycart Ag	anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
US20130078250A1 (en)	2011-08-23	2013-03-28	Oliver Ast	Bispecific t cell activating antigen binding molecules
RU2014109038A (ru)	2011-08-23	2015-09-27	Рош Гликарт Аг	Антитела к хондроитинсульфат протеогликану меланомы
KR101886983B1 (ko)	2011-08-23	2018-08-08	로슈 글리카트 아게	2 개의 ｆａｂ 단편을 포함하는 fc-부재 항체 및 이용 방법
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
BR112014005720A2 (pt)	2011-09-15	2017-12-12	Genentech Inc	método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
AR087918A1 (es)	2011-09-19	2014-04-23	Genentech Inc	Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
US20130089562A1 (en)	2011-10-05	2013-04-11	Genenthech, Inc.	Methods of treating liver conditions using notch2 antagonists
SI2766393T1 (sl)	2011-10-14	2018-10-30	F. Hoffmann-La Roche Ag	Protitelesa Anti-HtrA1 in postopki uporabe
WO2013056148A2 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
WO2013059531A1 (en)	2011-10-20	2013-04-25	Genentech, Inc.	Anti-gcgr antibodies and uses thereof
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
EP2776051A4 (de)	2011-10-28	2015-06-17	Hoffmann La Roche	Therapeutische kombinationen und verfahren zur behandlung von melanomen
CN104066748A (zh)	2011-11-21	2014-09-24	霍夫曼-拉罗奇有限公司	抗c-met抗体的纯化
ES2808152T3 (es)	2011-11-28	2021-02-25	Merck Patent Gmbh	Anticuerpos anti-PD-L1 y usos de los mismos
US20140335084A1 (en)	2011-12-06	2014-11-13	Hoffmann-La Roche Inc.	Antibody formulation
SG11201403223PA (en)	2011-12-22	2014-07-30	Hoffmann La Roche	Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
CN104011075B (zh)	2011-12-22	2017-06-06	弗·哈夫曼-拉罗切有限公司	表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
JP2015503907A (ja)	2011-12-22	2015-02-05	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	真核細胞のための全長抗体提示システムおよびその使用
WO2013096791A1 (en)	2011-12-23	2013-06-27	Genentech, Inc.	Process for making high concentration protein formulations
WO2013092998A1 (en)	2011-12-23	2013-06-27	Innate Pharma	Enzymatic conjugation of antibodies
US20150011431A1 (en)	2012-01-09	2015-01-08	The Scripps Research Institute	Humanized antibodies
EP2802603A4 (de)	2012-01-09	2015-11-04	Scripps Research Inst	Ultralange komplementaritätsbestimmungsbereiche und verwendungen davon
HK1204933A1 (en)	2012-01-13	2015-12-11	霍夫曼-拉罗奇有限公司	Biological markers for identifying patients for treatment with vegf antagonists
PE20141561A1 (es)	2012-01-18	2014-11-12	Genentech Inc	Anticuerpos anti-lrp5 y metodos de uso
JP2015506944A (ja)	2012-01-18	2015-03-05	ジェネンテック，インコーポレイテッド	Ｆｇｆ１９修飾薬を使用する方法
SG11201404486QA (en)	2012-01-31	2014-11-27	Genentech Inc	Anti-ig-e m1' antibodies and methods using same
SG11201404703WA (en)	2012-02-11	2014-09-26	Genentech Inc	R-spondin translocations and methods using the same
ES2676031T3 (es)	2012-02-15	2018-07-16	F. Hoffmann-La Roche Ag	Cromatografía de afinidad basada en el receptor Fc
US9676850B2 (en)	2012-02-24	2017-06-13	Abbvie Stemcentrx Llc	Anti SEZ6 antibodies and methods of use
CA2865404C (en)	2012-02-24	2019-08-27	Stem Centrx, Inc.	Dll3-binding antibodies and drug conjugates thereof to treat cancer
HK1202122A1 (en)	2012-03-13	2015-09-18	霍夫曼-拉罗奇有限公司	Combination therapy for the treatment of ovarian cancer
AU2013240261A1 (en)	2012-03-27	2014-09-18	Genentech, Inc.	Diagnosis and treatments relating to HER3 inhibitors
MX2014011582A (es)	2012-03-30	2014-11-21	Genentech Inc	Metodos y composiciones de diagnostico para el tratamiento de cancer.
AR090549A1 (es)	2012-03-30	2014-11-19	Genentech Inc	Anticuerpos anti-lgr5 e inmunoconjugados
US10114023B2 (en)	2012-04-18	2018-10-30	Massachusetts Institute Of Technology	Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of menaINV
AR090903A1 (es)	2012-05-01	2014-12-17	Genentech Inc	Anticuerpos e inmunoconjugados anti-pmel17
WO2013165590A1 (en)	2012-05-03	2013-11-07	Fibrogen, Inc.	Methods for treating idiopathic pulmonary fibrosis
WO2013170191A1 (en)	2012-05-11	2013-11-14	Genentech, Inc.	Methods of using antagonists of nad biosynthesis from nicotinamide
CA2870876C (en)	2012-05-23	2019-10-01	Genentech, Inc.	Selection method for therapeutic agents
KR102129636B1 (ko)	2012-05-31	2020-07-03	제넨테크, 인크.	Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
CA2875096A1 (en)	2012-06-15	2013-12-19	Genentech, Inc.	Anti-pcsk9 antibodies, formulations, dosing, and methods of use
WO2014006124A1 (en)	2012-07-04	2014-01-09	F. Hoffmann-La Roche Ag	Covalently linked antigen-antibody conjugates
MX353951B (es)	2012-07-04	2018-02-07	Hoffmann La Roche	Anticuerpos de anti-teofilina y metodos de uso.
BR112014030844A2 (pt)	2012-07-04	2019-10-15	Hoffmann La Roche	anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
CA2877009C (en)	2012-07-05	2023-10-03	Devin TESAR	Expression and secretion system
BR112015000437A2 (pt)	2012-07-09	2017-06-27	Genentech Inc	imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
JP6297549B2 (ja)	2012-07-09	2018-03-20	ジェネンテック，インコーポレイテッド	抗ｃｄ２２抗体および免疫複合体
AR091702A1 (es)	2012-07-09	2015-02-25	Genentech Inc	Anticuerpos anti-cd79b e inmunoconjugados
MX2015000357A (es)	2012-07-09	2015-05-12	Genentech Inc	Anticuerpos e inmunoconjugados anti-cd22.
EP2872894B1 (de)	2012-07-13	2019-04-17	Innate Pharma	Screening von konjugierten antikörpern
WO2014009465A1 (en)	2012-07-13	2014-01-16	Roche Glycart Ag	Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
AR092044A1 (es)	2012-08-07	2015-03-18	Roche Glycart Ag	Inmunoterapia mejorada
HK1204993A1 (en)	2012-08-07	2015-12-11	霍夫曼-拉罗奇有限公司	Combination therapy for the treatment of glioblastoma
SG11201408526SA (en)	2012-08-08	2015-03-30	Roche Glycart Ag	Interleukin-10 fusion proteins and uses thereof
WO2014023709A1 (en)	2012-08-09	2014-02-13	Roche Glycart Ag	Asgpr antibodies and uses thereof
US20140044675A1 (en)	2012-08-10	2014-02-13	Roche Glycart Ag	Interleukin-2 fusion proteins and uses thereof
JP6391574B2 (ja) *	2012-08-31	2018-09-26	アルゲン−エックスビーブイビーエー	種間標的内交差反応性を有する抗体分子を産生する方法
WO2014056783A1 (en)	2012-10-08	2014-04-17	Roche Glycart Ag	Fc-free antibodies comprising two fab-fragments and methods of use
WO2014071358A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel ntrk1 fusion molecules and uses thereof
ES2949394T3 (es)	2012-11-05	2023-09-28	Found Medicine Inc	Moléculas de fusión novedosas y usos de las mismas
AU2013343667A1 (en)	2012-11-08	2015-04-02	F. Hoffmann-La Roche Ag	HER3 antigen binding proteins binding to the beta-hairpin of HER3
WO2014072482A1 (en)	2012-11-09	2014-05-15	Innate Pharma	Recognition tags for tgase-mediated conjugation
US9284365B2 (en)	2012-11-13	2016-03-15	Genentech, Inc.	Anti-hemagglutinin antibodies and methods of use
WO2014107739A1 (en)	2013-01-07	2014-07-10	Eleven Biotherapeutics, Inc.	Antibodies against pcsk9
CA3150658A1 (en)	2013-01-18	2014-07-24	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
WO2014116749A1 (en)	2013-01-23	2014-07-31	Genentech, Inc.	Anti-hcv antibodies and methods of using thereof
MX2015010682A (es)	2013-02-22	2016-05-31	Stemcentrx Inc	Nuevos conjugados de anticuerpos y usos de los mismos.
HK1211235A1 (en)	2013-02-22	2016-05-20	霍夫曼-拉罗奇有限公司	Methods of treating cancer and preventing drug resistance
CA2901126C (en)	2013-02-25	2022-01-25	Genentech, Inc.	Methods and compositions for detecting and treating drug resistant akt mutant
DK2961771T3 (da)	2013-02-26	2020-03-02	Roche Glycart Ag	Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
EP2961773B1 (de)	2013-02-26	2019-03-20	Roche Glycart AG	Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
EP2961772A1 (de)	2013-02-26	2016-01-06	Roche Glycart AG	Anti-mcsp-antikörper
CN104936985A (zh)	2013-02-26	2015-09-23	罗切格利卡特公司	双特异性t细胞活化性抗原结合分子
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
US20140314778A1 (en)	2013-03-13	2014-10-23	Genentech, Inc.	Formulations with reduced oxidation
US10653779B2 (en)	2013-03-13	2020-05-19	Genentech, Inc.	Formulations with reduced oxidation
PT2968467T (pt)	2013-03-13	2020-07-28	Hoffmann La Roche	Formulações de oxidação reduzida
PL2968466T3 (pl)	2013-03-13	2018-11-30	F.Hoffmann-La Roche Ag	Preparaty o zmniejszonym utlenianiu
RU2694055C2 (ru)	2013-03-13	2019-07-09	Дженентек, Инк.	Составы антител
US10351626B2 (en)	2013-03-14	2019-07-16	The Scripps Research Institute	Targeting agent antibody conjugates and uses thereof
EA201591750A1 (ru)	2013-03-14	2016-05-31	Дженентек, Инк.	Антитела против b7-h4 и иммуноконъюгаты
BR112015022576A2 (pt)	2013-03-14	2017-10-24	Genentech Inc	produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
HK1220916A1 (zh)	2013-03-14	2017-05-19	基因泰克公司	治疗癌症和预防癌症药物抗性的方法
US9649375B2 (en)	2013-03-14	2017-05-16	The Administrators Of The Tulane Educational Fund	Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US9562099B2 (en)	2013-03-14	2017-02-07	Genentech, Inc.	Anti-B7-H4 antibodies and immunoconjugates
MX374811B (es)	2013-03-15	2025-03-06	Ac Immune Sa	Anticuerpos anti-tau y métodos de uso.
EP2968537A1 (de)	2013-03-15	2016-01-20	Genentech, Inc.	Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
AR095348A1 (es)	2013-03-15	2015-10-07	Genentech Inc	Medios de cultivo celular y métodos de producción de anticuerpos
MA38495A1 (fr)	2013-03-15	2017-08-31	Genentech Inc	Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EP2968582B1 (de)	2013-03-15	2020-07-01	Innate Pharma	Festphasen-tgase-vermittelte konjugation von antikörpern
PL2972373T3 (pl)	2013-03-15	2020-03-31	F. Hoffmann-La Roche Ag	Biomarkery i sposoby leczenia stanów związanych z PD-1 i PD-L1
KR20150131177A (ko)	2013-03-15	2015-11-24	제넨테크, 인크.	항-CRTh2 항체 및 그의 용도
EP4285988A3 (de)	2013-03-27	2024-03-06	Cedars-Sinai Medical Center	Behandlung von fibrose durch tl1a-hemmung
UA118028C2 (uk)	2013-04-03	2018-11-12	Рош Глікарт Аг	Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2983710B1 (de)	2013-04-09	2019-07-31	Annexon, Inc.	Behandlungsverfahren für neuromyelitis optica
CN105164158A (zh)	2013-04-29	2015-12-16	豪夫迈·罗氏有限公司	消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
US20160068613A1 (en)	2013-04-29	2016-03-10	Hoffmann-La Roche Inc.	Fc-receptor binding modified asymmetric antibodies and methods of use
SG11201508911PA (en)	2013-04-29	2015-11-27	Hoffmann La Roche	Human fcrn-binding modified antibodies and methods of use
EP4324480A3 (de)	2013-05-20	2024-05-08	F. Hoffmann-La Roche AG	Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
EP3010547B1 (de)	2013-06-20	2021-04-21	Innate Pharma	Enzymatische konjugation von polypeptiden
EP3010548A1 (de)	2013-06-21	2016-04-27	Innate Pharma	Enzymatische konjugation von polypeptiden
SG10202008809RA (en)	2013-07-09	2020-10-29	Annexon Inc	Anti-complement factor c1q antibodies and uses thereof
KR20250007687A (ko)	2013-07-16	2025-01-14	제넨테크, 인크.	Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
CN111518199A (zh)	2013-07-18	2020-08-11	图鲁斯生物科学有限责任公司	具有超长互补决定区的人源化抗体
US20160168231A1 (en)	2013-07-18	2016-06-16	Fabrus, Inc.	Antibodies with ultralong complementarity determining regions
EP3022295A4 (de)	2013-07-19	2017-03-01	Cedars-Sinai Medical Center	Signatur des tl1a (tnfsf15)-signalweges
PE20160190A1 (es)	2013-08-01	2016-04-28	Five Prime Therapeutics Inc	Anticuerpos anti-fgfr2iiib afucosilados
EP3038634A4 (de)	2013-08-28	2017-10-11	AbbVie Stemcentrx LLC	Neuartige sez6-modulatoren und verfahren zur verwendung
JP2016531915A (ja)	2013-08-28	2016-10-13	ステムセントリックス，インコーポレイテッド	部位特異的抗体コンジュゲーション方法および組成物
US10456470B2 (en)	2013-08-30	2019-10-29	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en)	2013-08-30	2020-04-14	Genentech, Inc.	Combination therapy for the treatment of glioblastoma
US20150071923A1 (en) *	2013-09-12	2015-03-12	Ge Wei	Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
RU2016109247A (ru)	2013-09-17	2017-10-19	Дженентек, Инк.	Способы применения антител к lgr5
CN104436157A (zh)	2013-09-23	2015-03-25	恩金生物有限公司	流感疫苗和治疗
CA2925310C (en)	2013-09-27	2022-12-06	Genentech, Inc.	Anti-pdl1 antibody formulations
CA2926084A1 (en)	2013-10-11	2015-04-16	Genentech, Inc.	Nsp4 inhibitors and methods of use
TWI658052B (zh)	2013-10-18	2019-05-01	美商建南德克公司	抗－ｒｓｐｏ抗體及使用方法
MX2016005159A (es)	2013-10-23	2016-07-05	Genentech Inc	Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
BR112016010169A2 (pt)	2013-11-06	2017-12-05	Stemcentrx Inc	anticorpos anticlaudina e métodos de uso
JP6478989B2 (ja) *	2013-11-07	2019-03-06	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗ｃｄ２０抗体とｂｔｋ阻害剤とを用いた併用療法
MY176237A (en)	2013-11-21	2020-07-24	Hoffmann La Roche	Anti-alpha-synuclein antibodies and methods of use
HRP20192052T1 (hr)	2013-12-09	2020-02-07	Allakos Inc.	Protutijela anti-siglec-8 te njihovi postupci i uporabe
AR098743A1 (es)	2013-12-13	2016-06-08	Genentech Inc	Anticuerpos e inmunoconjugados anti-cd33
SG11201604875PA (en)	2013-12-17	2016-07-28	Genentech Inc	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015095423A2 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
EP3647324A1 (de)	2013-12-17	2020-05-06	F. Hoffmann-La Roche AG	Verfahren zur krebsbehandlung unter verwendung von pd-1-achsen-bindenden antagonisten und taxanen
KR102357961B1 (ko)	2013-12-17	2022-02-08	제넨테크, 인크.	항-cd3 항체 및 이의 사용 방법
PT3083680T (pt)	2013-12-20	2020-03-17	Hoffmann La Roche	Anticorpos humanizados anti-tau(ps422) e métodos de utilização
TWI728373B (zh)	2013-12-23	2021-05-21	美商建南德克公司	抗體及使用方法
CN105873616B (zh)	2014-01-03	2020-06-05	豪夫迈·罗氏有限公司	共价连接的多肽毒素-抗体缀合物
MX373097B (es)	2014-01-03	2020-04-27	Hoffmann La Roche	Anticuerpos biespecíficos anti-hapteno/anti-receptor de barrera hematoencefálica, complejos de los mismos y su uso como transportadores a través de la barrera hematoencefálica.
CA2930154A1 (en)	2014-01-03	2015-07-09	F. Hoffmann-La Roche Ag	Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
CA2932547C (en)	2014-01-06	2023-05-23	F. Hoffmann-La Roche Ag	Monovalent blood brain barrier shuttle modules
CA2931986A1 (en)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Fc-region variants with modified fcrn- and maintained protein a-binding properties
WO2015112909A1 (en)	2014-01-24	2015-07-30	Genentech, Inc.	Methods of using anti-steap1 antibodies and immunoconjugates
JP6736467B2 (ja)	2014-02-04	2020-08-05	ジェネンテック，インコーポレイテッド	平滑化変異体及びその使用方法
RS58149B1 (sr)	2014-02-06	2019-02-28	Hoffmann La Roche	Fuzioni proteini interleukina-2 i njihova upotreba
EP3102231B1 (de)	2014-02-08	2019-09-11	F.Hoffmann-La Roche Ag	Verfahren zur behandlung von morbus alzheimer
AU2015213741B2 (en)	2014-02-08	2020-10-08	Genentech, Inc.	Methods of treating Alzheimer's Disease
CN111499741A (zh)	2014-02-12	2020-08-07	豪夫迈·罗氏有限公司	抗锯齿蛋白1抗体及使用方法
PE20161171A1 (es)	2014-02-21	2016-11-08	Genentech Inc	Anticuerpos bioespecificos anti-il-13/il-17 y sus usos referencia cruzada a solicitudes relacionadas
WO2015127407A1 (en)	2014-02-21	2015-08-27	Stemcentrx, Inc.	Anti-dll3 antibodies and drug conjugates for use in melanoma
US10183996B2 (en)	2014-02-28	2019-01-22	Allakos Inc.	Methods and compositions for treating Siglec-8 associated diseases
MX2016011637A (es)	2014-03-14	2017-04-13	Genentech Inc	Metodos y composiciones para secrecion de polipeptidos heterologos.
JP6744855B2 (ja)	2014-03-21	2020-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	抗体のｉｎｖｉｖｏでの半減期のｉｎｖｉｔｒｏでの予測
US20170107294A1 (en)	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
CA2943329A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
HUE046767T2 (hu)	2014-03-31	2020-03-30	Hoffmann La Roche	Anti-OX40 antitestek és alkalmazási eljárások
JP6666262B2 (ja)	2014-04-02	2020-03-13	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	多重特異性抗体の軽鎖誤対合を検出するための方法
EP3808778A1 (de)	2014-04-18	2021-04-21	Acceleron Pharma Inc.	Verfahren zur erhöhung der erythrozytenkonzentration und behandlung der sichelzellenanämie
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
RU2016150370A (ru)	2014-05-22	2018-06-26	Дженентек, Инк.	Антитела и иммуноконъюгаты против GPC3
BR112016025040A2 (en)	2014-05-23	2018-02-20	Genentech, Inc.	methods to determine mit biomarker expression, to treat cancer, to identify an individual with cancer, to predict whether an individual with cancer is more or less likely to respond effectively to treatment, to inhibit cell proliferation, and to treat nccrcc in an individual
EP3155015A1 (de)	2014-06-11	2017-04-19	F. Hoffmann-La Roche AG	Anti-lgr5-antikörper und verwendungen davon
CN114699529A (zh)	2014-06-13	2022-07-05	阿塞勒隆制药公司	用于治疗溃疡的方法和组合物
CN107073121A (zh)	2014-06-13	2017-08-18	基因泰克公司	治疗及预防癌症药物抗性的方法
WO2015195631A1 (en) *	2014-06-17	2015-12-23	Academia Sinica	HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP3164419B1 (de)	2014-06-26	2024-07-24	F. Hoffmann-La Roche AG	Anti-brdu-antikörper und verfahren zur verwendung
EP3680336A1 (de)	2014-07-03	2020-07-15	F. Hoffmann-La Roche AG	Polypeptidexpressionssysteme
ES2916923T3 (es)	2014-07-11	2022-07-06	Ventana Med Syst Inc	Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
EP3166627A1 (de)	2014-07-11	2017-05-17	Genentech, Inc.	Notch-signalweghemmung
WO2016011052A1 (en)	2014-07-14	2016-01-21	Genentech, Inc.	Diagnostic methods and compositions for treatment of glioblastoma
AR101210A1 (es)	2014-07-15	2016-11-30	Genentech Inc	Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
SI3608337T1 (sl)	2014-08-04	2024-07-31	F. Hoffmann - La Roche Ag	Biospecifične molekule za aktivacijo celic T in antigensko vezavo
IL279606B (en)	2014-08-08	2022-08-01	Alector Llc	Anti-trem2 antibodies and methods of using them
ES3034398T3 (en)	2014-08-28	2025-08-18	Bioatla Inc	Conditionally active chimeric antigen receptors for modified t-cells
TW201617368A (zh)	2014-09-05	2016-05-16	史坦森特瑞斯公司	新穎抗ｍｆｉ２抗體及使用方法
EP3191518B1 (de)	2014-09-12	2020-01-15	Genentech, Inc.	Anti-b7-h4-antikörper und immunkonjugate
TWI758784B (zh)	2014-09-12	2022-03-21	美商建南德克公司	抗her2抗體及免疫結合物
SG11201701627PA (en)	2014-09-12	2017-03-30	Genentech Inc	Anti-cll-1 antibodies and immunoconjugates
EP3193932B1 (de)	2014-09-15	2023-04-26	F. Hoffmann-La Roche AG	Antikörperformulierungen
WO2016042684A1 (ja) *	2014-09-16	2016-03-24	国立大学法人東京海洋大学	濃縮された生着能をもつ未分化生殖細胞を用いた生殖細胞系列への分化誘導方法
HK1243629A1 (zh)	2014-09-17	2018-07-20	基因泰克公司	包含抗her2抗体和吡咯并苯并二氮杂䓬的免疫缀合物
WO2016049214A1 (en)	2014-09-23	2016-03-31	Genentech, Inc.	METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
WO2016061389A2 (en)	2014-10-16	2016-04-21	Genentech, Inc.	Anti-alpha-synuclein antibodies and methods of use
EP3223865A4 (de)	2014-10-31	2018-10-03	Jounce Therapeutics, Inc.	Verfahren zur behandlung von erkrankungen mit b7-h4-bindenden antikörpern
CN106796235B (zh)	2014-11-03	2021-01-29	豪夫迈·罗氏有限公司	用于检测t细胞免疫子集的测定法及其使用方法
US20160160290A1 (en)	2014-11-03	2016-06-09	Genentech, Inc.	Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
SG10202008810QA (en)	2014-11-05	2020-10-29	Annexon Inc	Humanized anti-complement factor c1q antibodies and uses thereof
EP3215526A1 (de)	2014-11-05	2017-09-13	F. Hoffmann-La Roche AG	Verfahren zur herstellung von zweikettigen proteinen in bakterien
US10066002B2 (en)	2014-11-05	2018-09-04	Genentech, Inc.	Methods of producing two chain proteins in bacteria
WO2016073157A1 (en)	2014-11-06	2016-05-12	Genentech, Inc.	Anti-ang2 antibodies and methods of use thereof
DK3215528T3 (da)	2014-11-06	2019-10-07	Hoffmann La Roche	Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
EP3842453A1 (de)	2014-11-06	2021-06-30	F. Hoffmann-La Roche AG	Fc-region-varianten mit modifizierten eigenschaften der fcrn- und protein-a-bindung
EP3215536A1 (de)	2014-11-06	2017-09-13	F. Hoffmann-La Roche AG	Kombinationstherapie mit ox40-bindungsagonisten und tigit-inhibitoren
WO2016077369A1 (en)	2014-11-10	2016-05-19	Genentech, Inc.	Animal model for nephropathy and agents for treating the same
TWI705976B (zh)	2014-11-10	2020-10-01	美商建南德克公司	抗介白素-33抗體及其用途
EA037557B1 (ru)	2014-11-14	2021-04-14	Ф. Хоффманн-Ля Рош Аг	Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf
BR112017010198A2 (pt)	2014-11-17	2017-12-26	Genentech Inc	terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
US11008403B2 (en)	2014-11-19	2021-05-18	Genentech, Inc.	Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
CN107001473B (zh)	2014-11-19	2021-07-09	豪夫迈·罗氏有限公司	抗-运铁蛋白受体抗体及使用方法
EP3221364B1 (de)	2014-11-19	2020-12-16	Genentech, Inc.	Antikörper gegen bace1 und deren verwendung zur immuntherapie von nervenerkrankungen
WO2016081808A1 (en)	2014-11-20	2016-05-26	The Regents Of The University Of California	Compositions and methods related to hematologic recovery
DK3789402T3 (da)	2014-11-20	2022-09-19	Hoffmann La Roche	Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
CN107207609B (zh)	2014-11-20	2022-07-19	豪夫迈·罗氏有限公司	共同轻链和使用方法
MA41119A (fr)	2014-12-03	2017-10-10	Acceleron Pharma Inc	Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
AR102918A1 (es)	2014-12-05	2017-04-05	Genentech Inc	Anticuerpos anti-cd79b y métodos de uso
CN107206088A (zh)	2014-12-05	2017-09-26	豪夫迈·罗氏有限公司	使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
CN107207591A (zh)	2014-12-10	2017-09-26	豪夫迈·罗氏有限公司	血脑屏障受体抗体及使用方法
EP3234598B1 (de)	2014-12-18	2019-11-06	F.Hoffmann-La Roche Ag	Assay und verfahren zur bestimmung cdc-entlockender antikörper
WO2016098356A1 (en)	2014-12-19	2016-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-c5 antibodies and methods of use
KR102650420B1 (ko)	2014-12-19	2024-03-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
WO2016111947A2 (en)	2015-01-05	2016-07-14	Jounce Therapeutics, Inc.	Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
HK1244512A1 (zh)	2015-02-04	2018-08-10	健泰科生物技术公司	突变型smoothened及其使用方法
CN112142844B (zh)	2015-02-05	2025-07-25	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
BR112017018234A2 (pt)	2015-02-26	2018-04-17	Merck Patent Gmbh	inibidores de pd-1 / pd-l1 para o tratamento de câncer
CA2977285A1 (en)	2015-03-16	2016-09-22	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
WO2016146833A1 (en)	2015-03-19	2016-09-22	F. Hoffmann-La Roche Ag	Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
WO2016154177A2 (en)	2015-03-23	2016-09-29	Jounce Therapeutics, Inc.	Antibodies to icos
ES2768784T3 (es)	2015-03-23	2020-06-23	Bayer Pharma AG	Anticuerpos anti-CEACAM6 y usos de los mismos
MA41920B1 (fr)	2015-04-06	2021-05-31	Acceleron Pharma Inc	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
SI3280441T1 (sl)	2015-04-07	2022-01-31	Alector Llc	Protitelesa anti-sortilin in metoda njihove uporabe
CA2981183A1 (en)	2015-04-07	2016-10-13	Greg Lazar	Antigen binding complex having agonistic activity and methods of use
PL3286315T3 (pl)	2015-04-24	2021-11-02	F. Hoffmann-La Roche Ag	Sposoby identyfikacji bakterii zawierających polipeptydy wiążące
EP3778640A1 (de)	2015-05-01	2021-02-17	Genentech, Inc.	Maskierte anti-cd3-antikörper und verfahren zur verwendung
WO2016179194A1 (en)	2015-05-04	2016-11-10	Jounce Therapeutics, Inc.	Lilra3 and method of using the same
CN116196414A (zh)	2015-05-11	2023-06-02	豪夫迈·罗氏有限公司	治疗狼疮性肾炎的组合物和方法
JP7048319B2 (ja)	2015-05-12	2022-04-05	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
CA3025145A1 (en)	2015-05-22	2016-12-01	Translational Drug Development Llc	Benzamide and active compound compositions and methods of use
WO2016189091A1 (en)	2015-05-26	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016189118A1 (en)	2015-05-28	2016-12-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
PL3303632T5 (pl)	2015-05-29	2023-07-03	F. Hoffmann-La Roche Ag	Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
WO2016196343A1 (en)	2015-05-29	2016-12-08	Genentech, Inc.	Humanized anti-ebola virus glycoprotein antibodies and methods of use
EP3302552A1 (de)	2015-06-02	2018-04-11	H. Hoffnabb-La Roche Ag	Zusammensetzungen und verfahren zur verwendung von anti-il-34-antikörpern zur behandlung von neurologischen erkrankungen
CA3258972A1 (en)	2015-06-05	2025-04-17	Ac Immune Sa	TAU ANTIBODIES AND METHODS OF USING THEM
WO2016200835A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
CA2985483A1 (en)	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies
WO2016201388A2 (en)	2015-06-12	2016-12-15	Alector Llc	Anti-cd33 antibodies and methods of use thereof
EP3307779A2 (de)	2015-06-12	2018-04-18	Alector LLC	Anti-cd33-antikörper und verfahren zur verwendung davon
AR104987A1 (es)	2015-06-15	2017-08-30	Genentech Inc	Inmunoconjugados anticuerpo-fármaco unidos por enlazadores no peptídicos
JP6876629B2 (ja)	2015-06-16	2021-05-26	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Ｐｄ−ｌ１アンタゴニスト併用療法
CA2986928A1 (en)	2015-06-16	2016-12-22	Genentech, Inc.	Humanized and affinity matured antibodies to fcrh5 and methods of use
EP3310378B1 (de)	2015-06-16	2024-01-24	F. Hoffmann-La Roche AG	Anti-cll-1-antikörper und verfahren zur verwendung
JP2018526972A (ja)	2015-06-16	2018-09-20	ジェネンテック，インコーポレイテッド	抗ｃｄ３抗体及び使用方法
CN107787331B (zh)	2015-06-17	2022-01-11	豪夫迈·罗氏有限公司	抗her2抗体和使用方法
KR102689256B1 (ko)	2015-06-17	2024-07-30	제넨테크, 인크.	Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
JP6846362B2 (ja)	2015-06-17	2021-03-24	アラコスインコーポレイテッド	線維性疾患を処置するための方法および組成物
CN107921145A (zh)	2015-06-23	2018-04-17	拜耳医药股份有限公司	Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物（adc）
JP6691144B2 (ja)	2015-06-24	2020-04-28	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	目的に合わせた親和性を有する抗トランスフェリンレセプター抗体
JP7021955B2 (ja)	2015-06-24	2022-03-03	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｅｒ２及び血液脳関門受容体に特異的な三重特異性抗体及び使用方法
EP3744732B1 (de)	2015-06-24	2025-09-10	F. Hoffmann-La Roche AG	Humanisierte anti-tau(ps422)-antikörper und verfahren zur verwendung
WO2017001350A1 (en)	2015-06-29	2017-01-05	Ventana Medical Systems, Inc.	Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
CN108473573A (zh)	2015-06-29	2018-08-31	豪夫迈·罗氏有限公司	Ii型抗cd20抗体用于器官移植中
AU2016301380B2 (en)	2015-08-04	2021-07-01	Acceleron Pharma Inc.	Methods for treating myeloproliferative disorders
CN105384825B (zh)	2015-08-11	2018-06-01	南京传奇生物科技有限公司	一种基于单域抗体的双特异性嵌合抗原受体及其应用
BR112018001956A2 (pt)	2015-08-20	2018-09-11	Hoffmann La Roche	?método de medição de analitos e kit?
KR20180054639A (ko)	2015-08-28	2018-05-24	알렉터 엘엘씨	항-siglec-7 항체 및 이의 사용 방법
AU2016323088B2 (en)	2015-09-18	2020-12-10	Chugai Seiyaku Kabushiki Kaisha	IL-8-binding antibodies and uses thereof
EP3353206A1 (de)	2015-09-22	2018-08-01	Spring Bioscience Corporation	Anti-ox40-antikörper und diagnostische verwendungen davon
UA125432C2 (uk)	2015-09-23	2022-03-09	Дженентек, Інк.	Оптимізовані варіанти анти-vegf антитіл
EP3352791B1 (de)	2015-09-24	2019-10-30	AbVitro LLC	Hiv-antikörperzusammensetzungen und verfahren zur verwendung
CN113912724B (zh)	2015-09-25	2025-03-14	豪夫迈·罗氏有限公司	抗tigit抗体和使用方法
EP3356551B1 (de)	2015-09-29	2020-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur bestimmung der stoffwechsellage von b-lymphomen
WO2017058780A1 (en)	2015-09-30	2017-04-06	Merck Patent Gmbh	Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
AR106188A1 (es)	2015-10-01	2017-12-20	Hoffmann La Roche	Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AR106189A1 (es)	2015-10-02	2017-12-20	Hoffmann La Roche	ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017055393A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
RS62450B1 (sr)	2015-10-02	2021-11-30	Hoffmann La Roche	Anti-pd1 antitela i postupci primene
US20180282410A1 (en)	2015-10-02	2018-10-04	Hoffmann-La Roche Inc.	Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
WO2017055392A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
BR112018000835A2 (pt)	2015-10-02	2018-09-11	Hoffmann La Roche	molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
AU2016331931C1 (en)	2015-10-02	2020-01-16	Genentech, Inc.	Pyrrolobenzodiazepine antibody drug conjugates and methods of use
US20170096485A1 (en)	2015-10-02	2017-04-06	Hoffmann-La Roche Inc.	Bispecific t cell activating antigen binding molecules
JP6937746B2 (ja)	2015-10-02	2021-09-22	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
EP3356409A2 (de)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispezifische antigenbindende moleküle zur t-zellen-aktivierung
EP3356406A1 (de)	2015-10-02	2018-08-08	H. Hoffnabb-La Roche Ag	Bispezifische antikörper gegen menschliches cd20/gegen den menschlichen transferrinrezeptor und verfahren zur verwendung
WO2017055385A1 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
WO2017062672A2 (en)	2015-10-06	2017-04-13	Alector Llc	Anti-trem2 antibodies and methods of use thereof
US10556953B2 (en)	2015-10-12	2020-02-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
JP6621919B2 (ja)	2015-10-16	2019-12-18	ジェネンテック，インコーポレイテッド	束縛ジスルフィド薬物コンジュゲート
WO2017067944A1 (en)	2015-10-19	2017-04-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from triple negative breast cancer
JP6852065B2 (ja)	2015-10-20	2021-03-31	ジェネンテック，インコーポレイテッド	カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
EP3365372A1 (de)	2015-10-22	2018-08-29	Jounce Therapeutics, Inc.	Gensignaturen zur bestimmung der icos-expression
US10604577B2 (en)	2015-10-22	2020-03-31	Allakos Inc.	Methods and compositions for treating systemic mastocytosis
EP3184547A1 (de)	2015-10-29	2017-06-28	F. Hoffmann-La Roche AG	Anti-tpbg-antikörper und verfahren zur verwendung
WO2017075432A2 (en)	2015-10-29	2017-05-04	Alector Llc	Anti-siglec-9 antibodies and methods of use thereof
MX2018005036A (es)	2015-10-29	2018-08-01	Hoffmann La Roche	Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
PE20181009A1 (es)	2015-10-30	2018-06-26	Genentech Inc	ANTICUERPOS ANTI-HtrA1 Y METODOS DE USO DE LOS MISMOS
CN108289951A (zh)	2015-10-30	2018-07-17	豪夫迈·罗氏有限公司	抗-因子d抗体和缀合物
EP3370754A4 (de)	2015-11-04	2019-10-23	Acceleron Pharma Inc.	Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
CN108602884B (zh)	2015-11-08	2024-06-25	豪夫迈·罗氏有限公司	筛选多特异性抗体的方法
JP7072507B2 (ja)	2015-11-23	2022-05-20	アクセルロンファーマインコーポレイテッド	眼の障害を処置するための方法
JP7349787B2 (ja)	2015-11-23	2023-09-25	ファイヴプライムセラピューティクスインク	癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
EP3178848A1 (de)	2015-12-09	2017-06-14	F. Hoffmann-La Roche AG	Type ii anti-cd20 antikörper zur verringerung der bildung von antikörpern gegen medikamente
IL313608A (en)	2015-12-09	2024-08-01	Hoffmann La Roche	Antibody against CD20 type II to reduce the formation of antibodies against drugs
RU2742606C2 (ru)	2015-12-18	2021-02-09	Чугаи Сейяку Кабусики Кайся	Антитела к с5 и способы их применения
CA3002422C (en)	2015-12-18	2024-04-16	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CA3007491A1 (en)	2015-12-30	2017-07-06	Genentech, Inc.	Use of tryptophan derivatives for protein formulations
IL299759A (en)	2015-12-30	2023-03-01	Genentech Inc	Formulations with reduced polysorbate dissolution
EP3400443B1 (de)	2016-01-04	2020-09-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verwendung von pd-1 und tim-3 zur messung von cd8+ zellen zur vorhersage und behandlung von nierenzellkarzinom
US20200270365A1 (en)	2016-01-05	2020-08-27	Jiangsu Hengrui Medicine Co., Ltd.	Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
AU2017205089B2 (en)	2016-01-08	2023-10-05	F. Hoffmann-La Roche Ag	Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
US11103589B2 (en)	2016-01-08	2021-08-31	Apg Therapeutics, Inc.	Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof
CA3011739A1 (en)	2016-01-20	2017-07-27	Genentech, Inc.	High dose treatments for alzheimer's disease
WO2017129558A1 (en)	2016-01-25	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
AU2017213886B2 (en)	2016-02-04	2024-03-07	The California Institute For Biomedical Research	Humanized anti-CD3 antibodies, conjugates and uses thereof
AU2017213826A1 (en)	2016-02-04	2018-08-23	Curis, Inc.	Mutant smoothened and methods of using the same
CN114395624A (zh)	2016-02-29	2022-04-26	基因泰克公司	用于癌症的治疗和诊断方法
US11472877B2 (en)	2016-03-04	2022-10-18	Alector Llc	Anti-TREM1 antibodies and methods of use thereof
US10443054B2 (en)	2016-03-06	2019-10-15	Massachusetts Institute Of Technology	Methods for identifying and treating invasive/metastatic breast cancers
CN109476756B (zh)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	一种多特异性Fab融合蛋白及其用途
PL3430054T3 (pl)	2016-03-15	2022-05-23	Chugai Seiyaku Kabushiki Kaisha	Sposoby leczenia nowotworów z zastosowaniem antagonistów wiązania z osią PD-1 i przeciwciał anty-GPC3
JP7082945B2 (ja)	2016-03-17	2022-06-09	シーダーズ―シナイメディカルセンター	Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
WO2017162587A1 (en)	2016-03-22	2017-09-28	F. Hoffmann-La Roche Ag	Protease-activated t cell bispecific molecules
CN121431692A (zh)	2016-03-25	2026-01-30	豪夫迈·罗氏有限公司	多路总抗体和抗体缀合的药物量化测定法
EP3231813A1 (de)	2016-03-29	2017-10-18	F. Hoffmann-La Roche AG	Trimere kostimulatorische tnf-familien-ligandenhaltige antigenbindende moleküle
WO2017177013A1 (en)	2016-04-06	2017-10-12	Acceleron Pharma Inc.	Alk7 antagonists and uses thereof
EP3443004A1 (de)	2016-04-14	2019-02-20	H. Hoffnabb-La Roche Ag	Anti-rspo3-antikörper und verfahren zur verwendung
AU2017248644B2 (en)	2016-04-15	2019-10-31	Bioatla, Llc	Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses thereof
KR20190003958A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암의 치료 및 모니터링 방법
CN109154027A (zh)	2016-04-15	2019-01-04	豪夫迈·罗氏有限公司	用于监测和治疗癌症的方法
EP3889175A1 (de)	2016-05-02	2021-10-06	F. Hoffmann-La Roche AG	Der contorsbody - ein einkettiger targetbinder
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2017194442A1 (en)	2016-05-11	2017-11-16	F. Hoffmann-La Roche Ag	Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
EP3243836A1 (de)	2016-05-11	2017-11-15	F. Hoffmann-La Roche AG	C-terminal-fusionierte antigenbindende moleküle mit ligandentrimer der tnf-familie
JP7089483B2 (ja)	2016-05-11	2022-06-22	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	修飾された抗テネイシン抗体及び使用方法
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3243832A1 (de)	2016-05-13	2017-11-15	F. Hoffmann-La Roche AG	Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
LT3455261T (lt)	2016-05-13	2022-11-10	Bioatla, Inc.	Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas
EP3458101B1 (de)	2016-05-20	2020-12-30	H. Hoffnabb-La Roche Ag	Protac-antikörper-konjugate und verfahren zur verwendung
CA3025391A1 (en)	2016-05-26	2017-11-30	Merck Patent Gmbh	Pd-1 / pd-l1 inhibitors for cancer treatment
CN109313200B (zh)	2016-05-27	2022-10-04	豪夫迈·罗氏有限公司	用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017202890A1 (en)	2016-05-27	2017-11-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for predicting and treating myeloma
EP3252078A1 (de)	2016-06-02	2017-12-06	F. Hoffmann-La Roche AG	Typ ii anti-cd20 antikörper und anti-cd20/cd3 bispecific antikörper zur behandlung von krebs
CA3059010A1 (en)	2016-06-02	2018-12-06	F. Hoffmann-La Roche Ag	Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CN109311964B (zh)	2016-06-06	2022-11-04	豪夫迈·罗氏有限公司	用于眼科的具有增加的眼保留的融合蛋白
JP7043425B2 (ja)	2016-06-06	2022-03-29	ジェネンテック，インコーポレイテッド	シルベストロール抗体－薬物コンジュゲート及び使用方法
KR102680483B1 (ko)	2016-06-17	2024-07-01	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체 및 사용 방법
WO2017218891A1 (en)	2016-06-17	2017-12-21	Life Technologies Corporation	Site-specific crosslinking of antibodies
EP3475298A1 (de)	2016-06-24	2019-05-01	H. Hoffnabb-La Roche Ag	Multispezifische anti-polyubiquitin-antikörper
EP3475700A4 (de)	2016-06-26	2020-03-04	Gennova Biopharmaceuticals Limited	Antikörper-phagendisplay-bibliothek
JP6983824B2 (ja)	2016-07-04	2021-12-17	エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft	新規抗体フォーマット
EP3928784A1 (de)	2016-07-15	2021-12-29	Acceleron Pharma Inc.	Zusammensetzungen enthaltend actriia-polypeptide zur verwendung bei der behandlung von pulmonaler hypertonie
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
SI3490582T1 (sl)	2016-07-27	2024-09-30	Acceleron Pharma Inc.	Sestavki za uporabo proti zdravljenju mielofibroze
KR20230107408A (ko)	2016-07-29	2023-07-14	주노 쎄러퓨티크스 인코퍼레이티드	항-cd19 항체에 대한 항-이디오타입 항체
EP3494143B1 (de)	2016-08-03	2022-10-05	Cipla USA, Inc.	Plazomicin-antikörper und verfahren zur verwendung
MX2019001448A (es)	2016-08-05	2019-09-13	Chugai Pharmaceutical Co Ltd	Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018027204A1 (en)	2016-08-05	2018-02-08	Genentech, Inc.	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109476748B (zh)	2016-08-08	2023-05-23	豪夫迈·罗氏有限公司	用于癌症的治疗和诊断方法
RS64925B1 (sr)	2016-08-10	2023-12-29	Legend Biotech Ireland Ltd	Himerni antigenski receptori koji ciljaju bcma i postupci njihove upotrebe
WO2018031662A1 (en)	2016-08-11	2018-02-15	Genentech, Inc.	Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CA3032542A1 (en)	2016-08-12	2018-02-15	Genentech, Inc.	Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
US11168148B2 (en)	2016-09-07	2021-11-09	The Regents Of The University Of California	Antibodies to oxidation-specific epitopes
TW201825511A (zh)	2016-09-09	2018-07-16	美商艾斯合顧問有限公司	表現免疫檢查點調節子的溶瘤病毒
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN109689682B (zh)	2016-09-19	2022-11-29	豪夫迈·罗氏有限公司	基于补体因子的亲和层析
JP6995844B2 (ja)	2016-09-23	2022-02-04	ジェネンテック，インコーポレイテッド	アトピー性皮膚炎を治療するためのｉｌ－１３アンタゴニストの使用
BR112019005815A2 (pt)	2016-09-29	2019-06-25	Genentech Inc	métodos de tratamento de um indivíduo com câncer de mama, kit para o tratamento de câncer de mama e combinação de fármacos para terapia de câncer de mama
PL3519437T3 (pl)	2016-09-30	2022-01-17	F. Hoffmann-La Roche Ag	Przeciwciała dwuswoiste przeciwko p95HER2
AU2017340504A1 (en)	2016-10-05	2019-04-11	Acceleron Pharma, Inc.	Compositions and method for treating kidney disease
JP7050770B2 (ja)	2016-10-05	2022-04-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗体薬物コンジュゲートの調製方法
AU2017339517B2 (en)	2016-10-06	2024-03-14	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
MX2019003755A (es)	2016-10-06	2019-08-12	Pfizer	Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
CN110121509B (zh)	2016-10-26	2024-05-07	西达-赛奈医疗中心	中和抗tl1a单克隆抗体
WO2018081531A2 (en)	2016-10-28	2018-05-03	Ariad Pharmaceuticals, Inc.	Methods for human t-cell activation
US11078298B2 (en)	2016-10-28	2021-08-03	Banyan Biomarkers, Inc.	Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
US11555076B2 (en)	2016-10-29	2023-01-17	Genentech, Inc.	Anti-MIC antibodies and methods of use
HUE057559T2 (hu)	2016-11-02	2022-06-28	Jounce Therapeutics Inc	PD-1 elleni antitestek és alkalmazásaik
CN109906030B (zh)	2016-11-04	2022-03-18	安健基因公司	用于产生仅重链抗体的经基因修饰的非人动物和方法
MX2019005438A (es)	2016-11-15	2019-08-16	Genentech Inc	Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
TW201829463A (zh)	2016-11-18	2018-08-16	瑞士商赫孚孟拉羅股份公司	抗hla-g抗體及其用途
US10780080B2 (en)	2016-11-23	2020-09-22	Translational Drug Development, Llc	Benzamide and active compound compositions and methods of use
EP3548894B1 (de)	2016-12-02	2021-10-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur diagnose eines nierenzellkarzinoms
CN117820467A (zh)	2016-12-07	2024-04-05	基因泰克公司	抗tau抗体和使用方法
UA128383C2 (uk)	2016-12-07	2024-07-03	Дженентек, Інк.	Антитіло до тау-білка та спосіб його застосування
BR112018016717A2 (pt)	2016-12-16	2018-12-26	H Lundbeck As	agentes, usos e métodos
KR102669762B1 (ko)	2016-12-19	2024-05-30	에프. 호프만-라 로슈 아게	표적화된 4-1bb(cd137) 작용물질과의 병용 요법
MX2019006954A (es)	2016-12-20	2019-08-01	Hoffmann La Roche	Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
EP3559249A1 (de)	2016-12-21	2019-10-30	H. Hoffnabb-La Roche Ag	Verfahren zum in-vitro-glycoengineering von antikörpern
KR102390246B1 (ko)	2016-12-21	2022-04-22	에프. 호프만-라 로슈 아게	항체의 시험관내 글리코조작에 있어서의 효소의 재사용
AU2017384276B9 (en)	2016-12-21	2020-11-26	F. Hoffmann-La Roche Ag	In vitro glycoengineering of antibodies
JP7068323B2 (ja)	2017-02-02	2022-05-16	エフ．ホフマン－ラロシュアーゲー	少なくとも２種のペグ化された分析物特異的結合剤を使用する免疫アッセイ
MY197534A (en)	2017-02-10	2023-06-21	Genentech Inc	Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2019010295A (es)	2017-03-01	2019-11-21	Genentech Inc	Métodos de diagnóstico y terapéuticos para el cáncer.
IL269506B2 (en)	2017-03-22	2024-04-01	Genentech Inc	Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
MX2019011141A (es)	2017-03-22	2019-11-05	Genentech Inc	Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
EP3600427A1 (de)	2017-03-24	2020-02-05	INSERM - Institut National de la Santé et de la Recherche Médicale	Verfahren und zusammensetzungen zur behandlung von melanom
WO2018178029A1 (en)	2017-03-27	2018-10-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
WO2018178030A1 (en)	2017-03-27	2018-10-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating degenerative muscular and/or neurological conditions or diseases
SG10201911225WA (en)	2017-03-28	2020-01-30	Genentech Inc	Methods of treating neurodegenerative diseases
JP7205995B2 (ja)	2017-03-29	2023-01-17	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
JP7196094B2 (ja)	2017-03-29	2022-12-26	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
WO2018178074A1 (en)	2017-03-29	2018-10-04	F. Hoffmann-La Roche Ag	Trimeric antigen binding molecules specific for a costimulatory tnf receptor
IL269718B2 (en)	2017-03-30	2024-10-01	Merck Patent Gmbh	Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
EP3600308A1 (de)	2017-03-30	2020-02-05	INSERM - Institut National de la Santé et de la Recherche Médicale	Verfahren zur behandlung von mitochondrialen genetischen erkrankungen
KR102461885B1 (ko)	2017-04-03	2022-11-03	에프. 호프만-라 로슈 아게	항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
WO2018187191A1 (en)	2017-04-03	2018-10-11	Jounce Therapeutics, Inc	Compositions and methods for the treatment of cancer
EP3606947B1 (de)	2017-04-03	2022-12-21	F. Hoffmann-La Roche AG	Immunokonjugat von il-2 mit einem bispezifischen antikörper gerichtet gegen pd-1 und tim-3
BR112019018767A2 (pt)	2017-04-03	2020-05-05	Hoffmann La Roche	anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção
SG11201909344SA (en)	2017-04-05	2019-11-28	Hoffmann La Roche	Anti-lag3 antibodies
AU2018250875A1 (en)	2017-04-13	2019-10-03	F. Hoffmann-La Roche Ag	An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
SG11201909048TA (en)	2017-04-21	2019-11-28	Genentech Inc	Use of klk5 antagonists for treatment of a disease
KR102769634B1 (ko)	2017-04-27	2025-02-19	테사로, 인코포레이티드	림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
AU2018261887A1 (en)	2017-05-05	2019-12-05	Allakos Inc.	Methods and compositions for treating allergic ocular diseases
EP3401328A1 (de)	2017-05-10	2018-11-14	Bayer Pharma Aktiengesellschaft	Einstufige antikörperhumanisierung durch mischung der rahmenregionen einer golden-gate-basierten keimbahn
US11168129B2 (en)	2017-05-15	2021-11-09	University Of Rochester	Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
WO2018213316A1 (en)	2017-05-16	2018-11-22	Alector Llc	Anti-siglec-5 antibodies and methods of use thereof
WO2018213304A1 (en)	2017-05-16	2018-11-22	Five Prime Therapeutics, Inc.	Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
WO2019000223A1 (en)	2017-06-27	2019-01-03	Nanjing Legend Biotech Co., Ltd.	ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
WO2019002548A1 (en)	2017-06-29	2019-01-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	TREATMENT OF MIGRAINE WITH TREK1, TREK2 AGONIZATION OR HETEROMERS COMPRISING SAME
WO2019016310A1 (en)	2017-07-20	2019-01-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND COMPOSITIONS FOR TREATING CANCERS
AU2018304458B2 (en)	2017-07-21	2021-12-09	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
WO2019025299A1 (en)	2017-07-31	2019-02-07	F. Hoffmann-La Roche Ag	METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
AU2018310985A1 (en)	2017-08-03	2019-11-07	Alector Llc	Anti-CD33 antibodies and methods of use thereof
TW202511296A (zh)	2017-08-03	2025-03-16	美商阿列克特有限責任公司	抗trem2抗體及其使用方法
EP3444275A1 (de)	2017-08-16	2019-02-20	Exiris S.r.l.	Monoklonaler antikörper anti-fgfr4
WO2019046338A1 (en)	2017-08-28	2019-03-07	Angiex, Inc.	ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE
EP3684413A1 (de)	2017-09-20	2020-07-29	Chugai Seiyaku Kabushiki Kaisha	Dosierungsschema für kombinationstherapie unter verwendung von pd-1-achse-bindenden antagonisten und gegen gpc3 gerichteten wirkstoff
CN111108202B (zh)	2017-09-29	2024-10-22	中外制药株式会社	具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
JP2020536967A (ja)	2017-10-12	2020-12-17	イミュノウェイクインコーポレイテッド	Ｖｅｇｆｒ−抗体軽鎖融合タンパク質
US11826414B2 (en)	2017-10-23	2023-11-28	Cz Biohub Sf, Llc	Measurement of afucosylated IgG Fc glycans and related vaccination methods
EP3700567A4 (de)	2017-10-26	2021-09-29	The Regents of The University of California	Hemmung von oxidationsspezifischen epitopen zur behandlung von ischämischen reperfusionsschäden
CN111295392A (zh)	2017-11-01	2020-06-16	豪夫迈·罗氏有限公司	Compbody–多价靶结合物
EP3704155A2 (de)	2017-11-01	2020-09-09	F. Hoffmann-La Roche AG	Kombinationstherapie mit gezielten ox40-agonisten
PL3704146T3 (pl)	2017-11-01	2022-03-07	F. Hoffmann-La Roche Ag	Przeciwciało Contorsbody trifab
JP7544597B2 (ja)	2017-11-06	2024-09-03	ジェネンテック，インコーポレイテッド	がんの診断及び療法
EP3710589A4 (de)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	Anti-c1s-antikörper und verfahren zur verwendung
CA3084105A1 (en)	2017-12-21	2019-06-27	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a2/wt1
EP3502140A1 (de)	2017-12-21	2019-06-26	F. Hoffmann-La Roche AG	Kombinationstherapie von tumorabgezielten icos-agonisten mit t-zellenbispezifischen molekülen
EP3728321A1 (de)	2017-12-22	2020-10-28	F. Hoffmann-La Roche AG	Verwendung von pilra-bindenden mitteln zur behandlung einer erkrankung
SG11202004806SA (en)	2017-12-22	2020-06-29	Jounce Therapeutics Inc	Antibodies to lilrb2
SG11202004158QA (en)	2017-12-28	2020-06-29	Nanjing Legend Biotech Co Ltd	Single-domain antibodies and variants thereof against tigit
AU2018396964C1 (en)	2017-12-28	2024-10-03	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against PD-L1
JP7490565B2 (ja)	2017-12-29	2024-05-27	アレクトルエルエルシー	抗ｔｍｅｍ１０６ｂ抗体及びその使用方法
US20210072244A1 (en)	2018-01-04	2021-03-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma resistant
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
US11713353B2 (en)	2018-01-15	2023-08-01	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against PD-1
EP3740505A1 (de)	2018-01-16	2020-11-25	Lakepharma Inc.	Bispezifischer antikörper, der cd3 und ein anderes ziel bindet
US11472874B2 (en)	2018-01-31	2022-10-18	Alector Llc	Anti-MS4A4A antibodies and methods of use thereof
PE20211116A1 (es)	2018-02-08	2021-06-23	Genentech Inc	Moleculas biespecificas de union al antigeno y metodos de uso
TWI829667B (zh)	2018-02-09	2024-01-21	瑞士商赫孚孟拉羅股份公司	結合gprc5d之抗體
SG11202007564VA (en)	2018-02-09	2020-09-29	Genentech Inc	Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
US12364736B2 (en)	2018-02-09	2025-07-22	Acceleron Pharma Inc.	Methods for treating heterotopic ossification
EP3752134B1 (de)	2018-02-16	2024-12-04	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur behandlung von vitiligo
CN111836831A (zh)	2018-02-26	2020-10-27	豪夫迈·罗氏有限公司	用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
TW202000699A (zh)	2018-02-27	2020-01-01	瑞士商Ｅｃｓ前胃泌激素公司	將前胃泌激素作為生物標記用於免疫療法的技術
IL277174B2 (en)	2018-03-13	2025-12-01	Hoffmann La Roche	Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
TWI841551B (zh)	2018-03-13	2024-05-11	瑞士商赫孚孟拉羅股份公司	使用靶向4-1bb (cd137)之促效劑的組合療法
WO2019178362A1 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
US20200040103A1 (en)	2018-03-14	2020-02-06	Genentech, Inc.	Anti-klk5 antibodies and methods of use
CN116327926A (zh)	2018-03-15	2023-06-27	中外制药株式会社	对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
EP3775184B1 (de)	2018-03-29	2025-12-10	F. Hoffmann-La Roche AG	Modulation der laktogenen aktivität bei säugerzellen
US11958903B2 (en)	2018-03-30	2024-04-16	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against LAG-3 and uses thereof
JP7104458B2 (ja)	2018-04-02	2022-07-21	上海博威生物医薬有限公司	リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TW202011029A (zh)	2018-04-04	2020-03-16	美商建南德克公司	偵測及定量fgf21之方法
WO2019195561A2 (en)	2018-04-06	2019-10-10	BioLegend, Inc.	Anti-tetraspanin 33 agents and compositions and methods for making and using the same
EP3552631A1 (de)	2018-04-10	2019-10-16	Inatherys	Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
SG11202007961QA (en)	2018-04-13	2020-09-29	Hoffmann La Roche	Her2-targeting antigen binding molecules comprising 4-1bbl
AR114789A1 (es)	2018-04-18	2020-10-14	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de los mismos
AR115052A1 (es)	2018-04-18	2020-11-25	Hoffmann La Roche	Anticuerpos multiespecíficos y utilización de los mismos
WO2019209995A2 (en)	2018-04-25	2019-10-31	Precision Ibd, Inc.	Optimized anti-tl1a antibodies
EP3787678A1 (de)	2018-05-03	2021-03-10	University Of Rochester	Monoklonale neuraminidase-antikörper gegen influenza und ihre verwendungen
BR112020022145A2 (pt)	2018-05-04	2021-01-26	Merck Patent Gmbh	inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
US11319373B2 (en)	2018-05-25	2022-05-03	Alector Llc	Anti-SIRPA antibodies and methods of use thereof
WO2019227490A1 (en)	2018-06-01	2019-12-05	Tayu Huaxia Biotech Medical Group Co., Ltd.	Compositions and methods for imaging
BR112020023505A2 (pt)	2018-06-01	2021-03-30	Tayu Huaxia Biotech Medical Group Co., Ltd.	Composições e usos das mesmas para tratamento de doença ou condição
US20210238308A1 (en)	2018-06-04	2021-08-05	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule showing changed half-life in cytoplasm
TWI851577B (zh)	2018-06-07	2024-08-11	美商思進公司	喜樹鹼結合物
EP3801767A1 (de)	2018-06-08	2021-04-14	Alector LLC	Anti-siglec-7-antikörper und verfahren zur verwendung davon
JP2021526837A (ja)	2018-06-12	2021-10-11	アンジーエックス・インコーポレーテッド	抗体−オリゴヌクレオチドコンジュゲート
TWI890148B (zh)	2018-06-23	2025-07-11	美商建南德克公司	以pd-1軸結合拮抗劑、鉑劑及拓撲異構酶ii抑制劑治療肺癌之方法
MX2020013324A (es)	2018-06-29	2021-05-12	Alector Llc	Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
JP7554742B2 (ja)	2018-07-03	2024-09-20	マレンゴ・セラピューティクス，インコーポレーテッド	抗ｔｃｒ抗体分子およびその使用
KR20210031898A (ko)	2018-07-13	2021-03-23	난징 레전드 바이오테크 씨오., 엘티디.	전염병을 치료하기 위한 공동수용체 시스템
FI3618928T3 (fi)	2018-07-13	2023-04-21	Alector Llc	Anti-sortiliini-vasta-aineita ja menetelmiä niiden käyttämiseksi
MX2021000558A (es)	2018-07-18	2021-04-13	Genentech Inc	Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
MA53328A (fr)	2018-07-27	2021-06-09	Alector Llc	Anticorps anti-siglec-5 et leurs procédés d'utilisation
WO2020033485A1 (en)	2018-08-08	2020-02-13	Genentech, Inc.	Use of tryptophan derivatives and l-methionine for protein formulation
PE20210343A1 (es)	2018-08-10	2021-02-23	Chugai Pharmaceutical Co Ltd	Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
KR20210044243A (ko)	2018-08-13	2021-04-22	인히브릭스, 인크.	Ox40 결합 폴리펩티드 및 이의 용도
TW202021618A (zh)	2018-08-17	2020-06-16	美商２３與我有限公司	抗ｉｌ１ｒａｐ抗體及其使用方法
US12259395B2 (en)	2018-08-17	2025-03-25	Ab Studio Inc.	Catabodies and methods of use thereof
CA3108879A1 (en)	2018-08-21	2020-02-27	Albert Einstein College Of Medicine	Monoclonal antibodies against human tim-3
CN111417655A (zh)	2018-08-28	2020-07-14	润俊(中国)有限公司	抗cd3抗体叶酸生物偶联物及其用途
BR112021003016A2 (pt)	2018-08-31	2021-05-18	Alector Llc	anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
GB201814281D0 (en)	2018-09-03	2018-10-17	Femtogenix Ltd	Cytotoxic agents
CN112867735B (zh)	2018-09-07	2025-05-09	埃泰美德(香港)有限公司	双特异性抗原结合蛋白及其用途
EP3849545A1 (de)	2018-09-10	2021-07-21	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von neurofibromatose
WO2020052542A1 (en)	2018-09-10	2020-03-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against cll1 and constructs thereof
KR20210063330A (ko)	2018-09-19	2021-06-01	제넨테크, 인크.	방광암에 대한 치료 및 진단 방법
KR102739487B1 (ko)	2018-09-21	2024-12-10	제넨테크, 인크.	3중-음성 유방암에 대한 진단 방법
WO2020068557A1 (en)	2018-09-25	2020-04-02	BioLegend, Inc.	Anti-tlr9 agents and compositions and methods for making and using the same
CA3114024A1 (en)	2018-09-26	2020-04-02	Merck Patent Gmbh	Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
TW202028244A (zh)	2018-10-09	2020-08-01	美商建南德克公司	用於確定突觸形成之方法及系統
JP2022512684A (ja)	2018-10-11	2022-02-07	インヒブルクスインコーポレイテッド	Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物
EP3863721A1 (de)	2018-10-11	2021-08-18	Inhibrx, Inc.	5t4-einzeldomänenantikörper und therapeutische zusammensetzungen davon
EP3864045A2 (de)	2018-10-11	2021-08-18	Inhibrx, Inc.	Dll3-einzeldomänenantikörper und therapeutische zusammensetzungen davon
WO2020077257A1 (en)	2018-10-11	2020-04-16	Inhibrx, Inc.	Pd-1 single domain antibodies and therapeutic compositions thereof
EP3866785A1 (de)	2018-10-15	2021-08-25	Merck Patent GmbH	Kombinationstherapie unter verwendung von dna-alkylierenden mitteln und atr-inhibitoren
MX2021004348A (es)	2018-10-18	2021-05-28	Genentech Inc	Procedimientos de diagnóstico y terapéuticos para el cáncer de riñón sarcomatoide.
IL282441B2 (en)	2018-10-24	2025-07-01	Hoffmann La Roche	Conjugated chemical inducers of degradation and methods of use
MA54052A (fr)	2018-10-29	2022-02-09	Hoffmann La Roche	Formulation d'anticorps
US20210395390A1 (en)	2018-10-31	2021-12-23	Bayer Aktiengesellschaft	Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
WO2020092937A1 (en)	2018-11-02	2020-05-07	Annexon, Inc.	Compositions and methods for treating brain injury
EP3877407B1 (de)	2018-11-05	2026-03-11	F. Hoffmann-La Roche AG	Verfahren zur herstellung von zwei kettenproteinen in prokaryotischen wirtszellen
JP7682789B2 (ja)	2018-11-16	2025-05-26	アルバートアインシュタインカレッジオブメディスン	Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
WO2020104479A1 (en)	2018-11-20	2020-05-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US20220041719A1 (en)	2018-12-05	2022-02-10	Morphosys Ag	Multispecific antigen-binding molecules
MX2021006573A (es)	2018-12-06	2021-07-15	Genentech Inc	Tratamiento conjunto de linfoma difuso de linfocitos b grandes que comprende un inmunoconjugado anti-cd79b, un agente alquilante y un anticuerpo anti-cd20.
WO2020115261A1 (en)	2018-12-07	2020-06-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
JP2022513198A (ja)	2018-12-10	2022-02-07	ジェネンテック，インコーポレイテッド	Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201820554D0 (en)	2018-12-17	2019-01-30	Univ Oxford Innovation Ltd	BTLA antibodies
GB201820547D0 (en)	2018-12-17	2019-01-30	Oxford Univ Innovation	Modified antibodies
AR117327A1 (es)	2018-12-20	2021-07-28	23Andme Inc	Anticuerpos anti-cd96 y métodos de uso de estos
JP2022514290A (ja)	2018-12-20	2022-02-10	ジェネンテック，インコーポレイテッド	改変抗体ｆｃおよび使用方法
SG11202106251UA (en)	2018-12-21	2021-07-29	Ose Immunotherapeutics	Bifunctional anti-pd-1/sirpa molecule
AR117727A1 (es)	2018-12-21	2021-08-25	Hoffmann La Roche	Anticuerpos que se unen a cd3
SG11202105093RA (en)	2018-12-21	2021-06-29	Hoffmann La Roche	Tumor-targeted agonistic cd28 antigen binding molecules
JP7797198B2 (ja)	2018-12-21	2026-01-13	オーエスイー・イミュノセラピューティクス	ヒトｐｄ－１に対する二機能性分子
EP3898673A1 (de)	2018-12-21	2021-10-27	23Andme, Inc.	Anti-il-36-antikörper und verfahren zur verwendung davon
WO2020132231A1 (en)	2018-12-21	2020-06-25	Genentech, Inc.	Methods of producing polypeptides using a cell line resistant to apoptosis
WO2020127377A1 (en)	2018-12-21	2020-06-25	Ose Immunotherapeutics	Bifunctional anti-pd-1/il-7 molecule
WO2020127628A1 (en)	2018-12-21	2020-06-25	F. Hoffmann-La Roche Ag	Tumor-targeted superagonistic cd28 antigen binding molecules
WO2020127885A1 (en)	2018-12-21	2020-06-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Compositions for treating cancers and resistant cancers
WO2020132810A1 (en)	2018-12-24	2020-07-02	Generon (Shanghai) Corporation Ltd.	Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
SG11202106498XA (en)	2018-12-26	2021-07-29	Xilio Development Inc	Anti-ctla4 antibodies and methods of use thereof
CN113272327A (zh)	2018-12-30	2021-08-17	豪夫迈·罗氏有限公司	抗兔cd19抗体及其使用方法
AR117770A1 (es)	2019-01-07	2021-08-25	Inhibrx Inc	Polipéptidos que comprenden polipéptidos con il-2 modificada y usos de los mismos
TWI872040B (zh)	2019-01-14	2025-02-11	美商建南德克公司	用於癌症療法之ｒｎａ分子
CA3126778A1 (en)	2019-01-17	2020-07-23	Bayer Aktiengesellschaft	Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
CA3126359A1 (en)	2019-01-22	2020-07-30	Genentech, Inc.	Immunoglobulin a antibodies and methods of production and use
WO2020151572A1 (en)	2019-01-23	2020-07-30	Tayu Huaxia Biotech Medical Group Co., Ltd.	Anti-pd-l1 diabodies and the use thereof
JPWO2020153467A1 (ja)	2019-01-24	2021-12-02	中外製薬株式会社	新規がん抗原及びそれらの抗原に対する抗体
GB201901197D0 (en)	2019-01-29	2019-03-20	Femtogenix Ltd	G-A Crosslinking cytotoxic agents
US20220117911A1 (en)	2019-02-04	2022-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating blood-brain barrier
WO2020165374A1 (en)	2019-02-14	2020-08-20	Ose Immunotherapeutics	Bifunctional molecule comprising il-15ra
AU2020226893B2 (en)	2019-02-21	2025-02-27	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB2597851B (en)	2019-02-21	2024-05-29	Marengo Therapeutics Inc	Antibody molecules that bind to NKP30 and uses thereof
CN113710706A (zh)	2019-02-27	2021-11-26	豪夫迈·罗氏有限公司	用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
AU2020228060A1 (en)	2019-02-27	2021-09-16	Angiex, Inc.	Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
PH12021551720A1 (en)	2019-03-01	2022-03-28	Allogene Therapeutics Inc	Dll3 targeting chimeric antigen receptors and binding agents
KR102866290B1 (ko)	2019-03-08	2025-10-01	제넨테크, 인크.	세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
MY206650A (en)	2019-03-14	2024-12-30	Genentech Inc	Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
AU2020242042A1 (en)	2019-03-19	2021-09-16	Albert Einstein College Of Medicine	Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
EP3941488B1 (de)	2019-03-21	2025-05-14	Allogene Therapeutics, Inc.	Verfahren zur steigerung der abreicherungseffizienz von tcr-alpha-beta+-zellen
EP3946330A1 (de)	2019-03-29	2022-02-09	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren zur behandlung von keloid, hypertrophischen narben und/oder hyperpigmentierungserkrankungen
CN113677403B (zh)	2019-04-12	2024-12-27	豪夫迈·罗氏有限公司	包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
JP7593939B2 (ja)	2019-04-19	2024-12-03	ジェネンテック，インコーポレイテッド	抗ｍｅｒｔｋ抗体及びその使用方法
KR20220004028A (ko)	2019-04-26	2022-01-11	알로젠 테라퓨틱스 인코포레이티드	동종 car t 세포를 제조하는 방법
EP3963109A1 (de)	2019-04-30	2022-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur behandlung von melanom
AU2020270376A1 (en)	2019-05-03	2021-10-07	Genentech, Inc.	Methods of treating cancer with an anti-PD-L1 antibody
MX2021013417A (es)	2019-05-04	2021-12-10	Inhibrx Inc	Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
JP7525510B2 (ja)	2019-05-04	2024-07-30	インヒブルクスインコーポレイテッド	Ｃｄ３３結合性ポリペプチド及びその使用
CN114040926B (zh)	2019-05-04	2025-07-29	印希比生物科学有限公司	结合cd123的多肽及其用途
JP7550794B2 (ja)	2019-05-14	2024-09-13	ジェネンテック，インコーポレイテッド	濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
AU2020275348A1 (en)	2019-05-15	2021-12-09	Chugai Seiyaku Kabushiki Kaisha	An antigen-binding molecule, a pharmaceutical composition, and a method
US20200369759A1 (en)	2019-05-23	2020-11-26	Fibrogen, Inc.	Methods of treatment of muscular dystrophies
BR112021025077A2 (pt)	2019-06-11	2022-05-03	Alector Llc	Anticorpos anti-sortilina para uso em terapia
CN114127123A (zh)	2019-06-26	2022-03-01	豪夫迈·罗氏有限公司	结合cea的抗体与4-1bbl的融合
JP7354306B2 (ja)	2019-06-27	2023-10-02	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
CA3141050A1 (en)	2019-06-28	2020-12-30	Genentech, Inc.	Composition and methods for stabilizing liquid protein formulations
CN114051500A (zh)	2019-07-02	2022-02-15	豪夫迈·罗氏有限公司	包含白细胞介素-2突变体和抗cd8抗体的免疫缀合物
AR119393A1 (es)	2019-07-15	2021-12-15	Hoffmann La Roche	Anticuerpos que se unen a nkg2d
US12421292B2 (en)	2019-07-17	2025-09-23	Legend Biotech Ireland Limited	Anti-DLL3 chimeric antigen receptors and uses thereof
BR112022001460A2 (pt)	2019-07-31	2022-03-22	Hoffmann La Roche	Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
WO2021018925A1 (en)	2019-07-31	2021-02-04	F. Hoffmann-La Roche Ag	Antibodies binding to gprc5d
AU2020321969A1 (en)	2019-07-31	2022-03-17	Alector Llc	Anti-MS4A4A antibodies and methods of use thereof
WO2021024209A1 (en)	2019-08-06	2021-02-11	Aprinoia Therapeutics Inc.	Antibodies that bind to pathological tau species and uses thereof
CN119409834A (zh)	2019-08-12	2025-02-11	北京恩瑞尼生物科技股份有限公司	用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
BR112022003635A2 (pt)	2019-09-04	2022-05-24	Pf Medicament	Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
WO2021048292A1 (en)	2019-09-11	2021-03-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
AU2020345913B2 (en)	2019-09-12	2026-02-12	Genentech, Inc.	Compositions and methods of treating lupus nephritis
US12312414B2 (en)	2019-09-18	2025-05-27	Genentech, Inc.	Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
CR20220149A (es)	2019-09-20	2022-05-23	Genentech Inc	Dosis para anticuerpos anti-triptasa
CR20220127A (es)	2019-09-27	2022-05-27	Genentech Inc	Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
EP4036116A4 (de)	2019-09-27	2024-01-24	Nanjing GenScript Biotech Co., Ltd.	Anti-vhh-domänen-antikörper und verwendung davon
US11760801B2 (en)	2019-09-27	2023-09-19	Janssen Biotech, Inc.	Anti-CEACAM antibodies and uses thereof
WO2021063968A1 (en)	2019-09-30	2021-04-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and composition for diagnosing chronic obstructive pulmonary disease
US20220354811A1 (en)	2019-10-03	2022-11-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for modulating macrophages polarization
AU2020365836A1 (en)	2019-10-18	2022-04-28	F. Hoffmann-La Roche Ag	Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma
CN116063517A (zh)	2019-10-24	2023-05-05	普罗米修斯生物科学公司	Tnf样配体1a(tl1a)的人源化抗体及其用途
US20230044248A1 (en)	2019-11-01	2023-02-09	Ares Trading S.A.	COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
BR112022008295A2 (pt)	2019-11-05	2022-07-26	Merck Patent Gmbh	Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
CA3151307A1 (en)	2019-11-05	2021-05-14	Merck Patent Gmbh	Anti-tigit antibodies and uses thereof
CA3155922A1 (en)	2019-11-06	2021-05-14	Huang Huang	Diagnostic and therapeutic methods for treatment of hematologic cancers
TWI895295B (zh)	2019-11-12	2025-09-01	美商方得生醫療公司	偵測編碼新生抗原之融合基因之方法
BR112022008172A2 (pt)	2019-11-15	2022-07-12	Hoffmann La Roche	Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
JP2023505279A (ja)	2019-12-05	2023-02-08	アレクトルエルエルシー	抗ｔｒｅｍ２抗体の使用方法
CN115916817A (zh)	2019-12-06	2023-04-04	朱诺治疗学股份有限公司	针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
US12570749B2 (en)	2019-12-06	2026-03-10	Juno Therapeutics, Inc.	Anti-idiotypic antibodies to GPRC5D-targeted binding domains and related compositions and methods
JP2023504748A (ja)	2019-12-09	2023-02-06	ジェネンテック，インコーポレイテッド	抗ｐｄ－ｌ１抗体製剤
KR20220127243A (ko)	2019-12-12	2022-09-19	알렉터 엘엘씨	항-cd33 항체의 사용 방법
BR112022011570A2 (pt)	2019-12-13	2022-12-13	Alector Llc	Anticorpos anti-mertk e métodos de uso dos mesmos
IL293423A (en)	2019-12-13	2022-07-01	Genentech Inc	Anti-ly6g6d antibodies and methods of use
CR20220256A (es)	2019-12-18	2022-08-31	Hoffmann La Roche	Anticuerpos que se unen a hla-a2/mage-a4
CN115515678A (zh)	2019-12-23	2022-12-23	基因泰克公司	载脂蛋白l1特异性抗体及其使用方法
CR20220357A (es)	2019-12-27	2022-08-24	Chugai Pharmaceutical Co Ltd	Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
GB2609554B (en)	2020-01-03	2025-08-20	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
CA3162009A1 (en)	2020-01-09	2021-07-15	F. Hoffmann-La Roche Ag	New 4-1bbl trimer-containing antigen binding molecules
CN110818795B (zh)	2020-01-10	2020-04-24	上海复宏汉霖生物技术股份有限公司	抗tigit抗体和使用方法
US20230076415A1 (en)	2020-01-17	2023-03-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
MX2022009170A (es)	2020-01-27	2022-08-17	Genentech Inc	Procedimientos para el tratamiento del cancer con un anticuerpo antagonista anti-tigit.
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
JP7789002B2 (ja)	2020-01-29	2025-12-19	インヒブルクスバイオサイエンシズインコーポレイテッド	Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
BR112022015077A2 (pt)	2020-01-31	2022-10-04	Genentech Inc	Métodos para induzir células t cd8+ específicas de neoepítopos em um indivíduo com um tumor e para induzir o tráfico de células t cd8+, vacinas de rna, vacina de rna para uso e antagonistas de ligação
AU2021218927B2 (en)	2020-02-10	2024-12-19	Shanghai Escugen Biotechnology Co., Ltd.	Claudin 18.2 antibody and use thereof
WO2021160154A1 (zh)	2020-02-10	2021-08-19	上海诗健生物科技有限公司	Cldn18.2抗体及其用途
TWI895351B (zh)	2020-02-12	2025-09-01	日商中外製藥股份有限公司	用於癌症之治療的抗cd137抗原結合分子
WO2021163064A2 (en)	2020-02-14	2021-08-19	Jounce Therapeutics, Inc.	Antibodies and fusion proteins that bind to ccr8 and uses thereof
CA3167851A1 (en)	2020-02-24	2021-09-02	Francesca CIGNARELLA	Methods of use of anti-trem2 antibodies
WO2021173889A1 (en)	2020-02-26	2021-09-02	Ambrx, Inc.	Uses of anti-cd3 antibody folate bioconjugates
JP7791826B2 (ja)	2020-02-28	2025-12-24	上海復宏漢霖生物技術股▲フン▼有限公司	抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
CN115066440A (zh)	2020-02-28	2022-09-16	上海复宏汉霖生物技术股份有限公司	抗cd137构建体及其用途
WO2021177980A1 (en)	2020-03-06	2021-09-10	Genentech, Inc.	Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
AU2021236306A1 (en)	2020-03-13	2022-09-15	Genentech, Inc.	Anti-interleukin-33 antibodies and uses thereof
US11919948B2 (en)	2020-03-19	2024-03-05	Genentech, Inc.	Isoform-selective anti-TGFβ antibodies and methods of use
WO2021194913A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Tie2-binding agents and methods of use
JP2023518841A (ja)	2020-03-26	2023-05-08	ジェネンテック，インコーポレイテッド	宿主細胞タンパク質が減少した修飾哺乳動物細胞
WO2021202590A1 (en)	2020-03-31	2021-10-07	Alector Llc	Anti-mertk antibodies and methods of use thereof
WO2021202235A1 (en)	2020-04-01	2021-10-07	University Of Rochester	Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
US12523662B2 (en)	2020-04-02	2026-01-13	Seattle Children's Hospital	Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia
WO2021198511A1 (en)	2020-04-03	2021-10-07	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treatment of sars-cov-2 infection
EP4127724A1 (de)	2020-04-03	2023-02-08	Genentech, Inc.	Therapeutische und diagnostische verfahren für krebs
IL296992A (en)	2020-04-03	2022-12-01	Alector Llc	Methods for using anti-trem2 antibodies
WO2021207348A1 (en)	2020-04-07	2021-10-14	Albert Einstein College Of Medicine	Method of treating and preventing ocular disease with hsv-2 delta gd
WO2021209458A1 (en)	2020-04-14	2021-10-21	Ares Trading S.A.	Combination treatment of cancer
CR20220512A (es)	2020-04-15	2022-11-07	Hoffmann La Roche	Inmunoconjugados
IL297541A (en)	2020-04-24	2022-12-01	Genentech Inc	Methods for using anti-cd79b immunoconjugates
EP4143225A4 (de)	2020-04-27	2024-05-15	The Regents of the University of California	Isoform-unabhängige antikörper gegen lipoprotein(a)
WO2021222935A2 (en)	2020-04-28	2021-11-04	The Rockefeller University	Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
WO2021222167A1 (en)	2020-04-28	2021-11-04	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
TW202200212A (zh)	2020-05-03	2022-01-01	中國大陸商聯寧（蘇州）生物製藥有限公司	包含抗-trop-2抗體之抗體藥物結合物
WO2021224401A1 (en)	2020-05-07	2021-11-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for determining a reference range of β-galactose exposure platelet
WO2021228917A1 (en)	2020-05-15	2021-11-18	F. Hoffmann-La Roche Ag	Prevention of visible particle formation in parenteral protein solutions
CN115605185A (zh)	2020-05-19	2023-01-13	豪夫迈·罗氏有限公司（Ch）	螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
CA3178417A1 (en)	2020-05-29	2021-12-02	Yu Chen	Anti-cd200r1 antibodies and methods of use thereof
US20230235075A1 (en)	2020-06-02	2023-07-27	Dynamicure Biotechnology Llc	Anti-cd93 constructs and uses thereof
CN116529260A (zh)	2020-06-02	2023-08-01	当康生物技术有限责任公司	抗cd93构建体及其用途
JP2023527578A (ja)	2020-06-05	2023-06-29	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	眼疾患を処置するための方法及び医薬組成物
US20230340081A1 (en)	2020-06-08	2023-10-26	Hoffmann-La Roche Inc.	Anti-hbv antibodies and methods of use
WO2021249969A1 (en)	2020-06-10	2021-12-16	Merck Patent Gmbh	Combination product for the treatment of cancer diseases
GB202008860D0 (en)	2020-06-11	2020-07-29	Univ Oxford Innovation Ltd	BTLA antibodies
WO2021252977A1 (en)	2020-06-12	2021-12-16	Genentech, Inc.	Methods and compositions for cancer immunotherapy
JP2023531406A (ja)	2020-06-16	2023-07-24	ジェネンテック，インコーポレイテッド	トリプルネガティブ乳がんを処置するための方法および組成物
CA3181672A1 (en)	2020-06-18	2021-12-23	Shi Li	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
JP7815150B2 (ja)	2020-06-19	2026-02-17	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	プロテアーゼ活性化型ｔ細胞二重特異性抗体
TWI811703B (zh)	2020-06-19	2023-08-11	瑞士商赫孚孟拉羅股份公司	與ｃｄ３及ｃｄ１９結合之抗體
JP2023529981A (ja)	2020-06-19	2023-07-12	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	免疫活性化Ｆｃドメイン結合分子
TW202216767A (zh)	2020-06-19	2022-05-01	瑞士商赫孚孟拉羅股份公司	與ＣＤ３及ＦｏｌＲ１結合之抗體
WO2021255146A1 (en)	2020-06-19	2021-12-23	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and cea
PH12022500027A1 (en)	2020-06-19	2024-03-25	Hoffmann La Roche	Antibodies binding to cd3
CA3183475A1 (en)	2020-06-22	2021-12-30	Thomas Huber	Anti-il-36 antibodies and methods of use thereof
US12049515B2 (en)	2020-06-23	2024-07-30	Hoffmann-La Roche Inc.	Agonistic CD28 antigen binding molecules targeting Her2
US20220041672A1 (en)	2020-06-24	2022-02-10	Genentech, Inc.	Apoptosis resistant cell lines
JP2023531067A (ja)	2020-06-25	2023-07-20	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
AU2021299552A1 (en)	2020-07-02	2023-02-02	Inhibrx Biosciences, Inc.	Polypeptides comprising modified IL-2 polypeptides and uses thereof
EP4178529A1 (de)	2020-07-07	2023-05-17	F. Hoffmann-La Roche AG	Alternative tenside als stabilisatoren für therapeutische proteinformulierungen
WO2022008597A1 (en)	2020-07-08	2022-01-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of infectious diseases
PH12023550112A1 (en)	2020-07-17	2024-06-24	Genentech Inc	Anti-notch2 antibodies and methods of use
CA3188649A1 (en)	2020-07-21	2022-01-27	Genentech, Inc.	Antibody-conjugated chemical inducers of degradation of brm and methods thereof
WO2022023379A1 (en)	2020-07-28	2022-02-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for preventing and treating a cancer
GB2597532A (en)	2020-07-28	2022-02-02	Femtogenix Ltd	Cytotoxic compounds
CA3190328A1 (en)	2020-07-29	2022-02-03	Dynamicure Biotechnology Llc	Anti-cd93 constructs and uses thereof
EP4189121A1 (de)	2020-08-03	2023-06-07	Genentech, Inc.	Diagnostische und therapeutische verfahren für lymphom
KR20230095918A (ko)	2020-08-05	2023-06-29	주노 쎄러퓨티크스 인코퍼레이티드	Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
JP2023539201A (ja)	2020-08-28	2023-09-13	ジェネンテック，インコーポレイテッド	宿主細胞タンパク質のＣＲＩＳＰＲ／Ｃａｓ９マルチプレックスノックアウト
AU2021337687A1 (en)	2020-09-04	2023-03-23	CSPC Megalith Biopharmaceutical Co., Ltd.,	Nectin-4 antibodies and uses thereof
WO2022053715A1 (en)	2020-09-14	2022-03-17	Ichnos Sciences SA	Antibodies that bind to il1rap and uses thereof
CA3194792A1 (en)	2020-09-15	2022-03-24	Bayer Aktiengesellschaft	Novel anti-a2ap antibodies and uses thereof
EP3970752A1 (de)	2020-09-17	2022-03-23	Merck Patent GmbH	Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
CN118126189A (zh)	2020-09-28	2024-06-04	安济盛生物医药有限公司	抗硬骨抑素构建体及其用途
WO2022064049A1 (en)	2020-09-28	2022-03-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for diagnosing brucella infection
TWI836278B (zh)	2020-10-05	2024-03-21	美商建南德克公司	用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
MX2023004342A (es)	2020-10-20	2023-05-04	Hoffmann La Roche	Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2.
TW202233671A (zh)	2020-10-20	2022-09-01	美商建南德克公司	Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法
WO2022084300A1 (en)	2020-10-20	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for diagnosis and monitoring form of coronavirus infection
WO2022084531A1 (en)	2020-10-23	2022-04-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating glioma
WO2022093981A1 (en)	2020-10-28	2022-05-05	Genentech, Inc.	Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022090527A1 (en)	2020-11-02	2022-05-05	Ares Trading S.A.	Combination treatment of cancer
CA3196550A1 (en)	2020-11-02	2022-05-05	Yan Lan	Combination treatment of cancer
MX2023005132A (es)	2020-11-04	2023-05-25	Genentech Inc	Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
WO2022098628A2 (en)	2020-11-04	2022-05-12	Genentech, Inc.	Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
WO2022098870A1 (en)	2020-11-04	2022-05-12	The Rockefeller University	Neutralizing anti-sars-cov-2 antibodies
KR20230095113A (ko)	2020-11-04	2023-06-28	제넨테크, 인크.	항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
KR20230109674A (ko)	2020-11-16	2023-07-20	에프. 호프만-라 로슈 아게	Fab 고 만노스 당형
EP4244391A1 (de)	2020-11-16	2023-09-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
IL303349A (en)	2020-12-02	2023-08-01	Shanghai Henlius Biotech Inc	ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
US20240101681A1 (en)	2020-12-02	2024-03-28	Alector Llc	Methods of use of anti-sortilin antibodies
JP2023551563A (ja)	2020-12-04	2023-12-08	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	ｐＨ依存性変異体インターロイキン－２ポリペプチド
EP4259782A1 (de)	2020-12-14	2023-10-18	Allogene Therapeutics, Inc.	Verfahren und reagenzien zur charakterisierung von car-t-zellen für therapien
MX2023007133A (es)	2020-12-17	2023-06-27	Hoffmann La Roche	Anticuerpos anti-hla-g y uso de estos.
WO2022140797A1 (en)	2020-12-23	2022-06-30	Immunowake Inc.	Immunocytokines and uses thereof
WO2022148853A1 (en)	2021-01-11	2022-07-14	F. Hoffmann-La Roche Ag	Immunoconjugates
WO2022155324A1 (en)	2021-01-15	2022-07-21	The Rockefeller University	Neutralizing anti-sars-cov-2 antibodies
TW202245811A (zh)	2021-02-03	2022-12-01	美商異基因治療有限公司	用於ｃａｒｔ細胞藥物產品的調配物與製程
MX2023009567A (es)	2021-02-19	2023-08-22	Inhibrx Inc	Formulaciones de polipeptidos de union a dr5.
WO2022180145A2 (en)	2021-02-26	2022-09-01	Bayer Aktiengesellschaft	Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
AU2022230384A1 (en)	2021-03-01	2023-09-07	Xilio Development, Inc.	Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
TW202317612A (zh)	2021-03-01	2023-05-01	美商艾希利歐發展股份有限公司	用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合
WO2022184082A1 (en)	2021-03-03	2022-09-09	Sorrento Therapeutics, Inc.	Antibody-drug conjugates comprising an anti-bcma antibody
US20240158503A1 (en)	2021-03-03	2024-05-16	Pierre Fabre Medicament	Anti-vsig4 antibody or antigen binding fragment and uses thereof
TW202302646A (zh)	2021-03-05	2023-01-16	美商當康生物科技有限公司	抗vista構築體及其用途
US20240092856A1 (en)	2021-03-09	2024-03-21	Hoffmann-La Roche Inc.	Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
JP2024512382A (ja)	2021-03-09	2024-03-19	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｐｄ－１標的化ｉｌ－２バリアント免疫コンジュゲートと抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体の併用療法
KR20230148226A (ko)	2021-03-10	2023-10-24	이뮤노웨이크 인크.	면역조절 분자 및 이의 용도
JP2024512377A (ja)	2021-03-12	2024-03-19	ジェネンテック，インコーポレイテッド	抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
TW202300521A (zh)	2021-03-15	2023-01-01	美商建南德克公司	治療狼瘡性腎炎的組成物及方法
EP4308118A1 (de)	2021-03-17	2024-01-24	Institut National de la Santé et de la Recherche Médicale (INSERM)	Verfahren und zusammensetzungen zur melanombehandlung
JP2024512002A (ja)	2021-03-18	2024-03-18	アレクトルエルエルシー	抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
WO2022197877A1 (en)	2021-03-19	2022-09-22	Genentech, Inc.	Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
EP4314814A1 (de)	2021-03-22	2024-02-07	Juno Therapeutics, Inc.	Verfahren zur bestimmung der wirksamkeit einer therapeutischen zellzusammensetzung
JP2024511420A (ja)	2021-03-22	2024-03-13	ジュノーセラピューティクスインコーポレイテッド	ウイルスベクター粒子の効力を評価する方法
WO2022204274A1 (en)	2021-03-23	2022-09-29	Alector Llc	Anti-tmem106b antibodies for treating and preventing coronavirus infections
JP2024511424A (ja)	2021-03-25	2024-03-13	ダイナミキュアバイオテクノロジーエルエルシー	抗ｉｇｆｂｐ７構築物およびその使用
JP2024512709A (ja)	2021-03-30	2024-03-19	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	プロテアーゼ活性化ポリペプチド
US12384843B2 (en)	2021-03-30	2025-08-12	Bayer Aktiengesellschaft	Anti-semaphorin 3A antibodies
WO2022216898A1 (en)	2021-04-09	2022-10-13	Genentech, Inc.	Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
AR125344A1 (es)	2021-04-15	2023-07-05	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-c1s
EP4326855A1 (de)	2021-04-19	2024-02-28	Genentech, Inc.	Modifizierte säugerzellen
US20240158861A1 (en)	2021-04-23	2024-05-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating cell senescence accumulation related disease
WO2022228706A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
JP2024519415A (ja)	2021-04-30	2024-05-13	ピエールファーブルメディカモン	新しい安定な抗ｖｉｓｔａ抗体
CA3213632A1 (en)	2021-04-30	2022-11-03	F. Hoffmann-La Roche Ag	Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
JP2024517872A (ja)	2021-05-03	2024-04-23	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	ＨＥＲ２を標的にするＦｃ抗原結合性フラグメント－薬物抱合体
WO2022235867A2 (en)	2021-05-06	2022-11-10	The Rockefeller University	Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
MX2023013264A (es)	2021-05-12	2023-11-30	Genentech Inc	Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
US12384844B2 (en)	2021-05-14	2025-08-12	Genentech, Inc.	Agonists of TREM2
KR20240058050A (ko)	2021-05-18	2024-05-03	유니버시티 오브 테네시 리서치 파운데이션	아밀로이드 장애 치료를 위한 항체-펩티드 융합 단백질
EP4341385A1 (de)	2021-05-21	2024-03-27	Genentech, Inc.	Modifizierte zellen zur herstellung eines rekombinanten produkts von interesse
IL308818A (en)	2021-05-25	2024-01-01	Merck Patent Gmbh	Egfr targeting fc antigen binding fragment-drug conjugates
AR126009A1 (es)	2021-06-02	2023-08-30	Hoffmann La Roche	Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4155321A1 (de)	2021-06-04	2023-03-29	Chugai Seiyaku Kabushiki Kaisha	Anti-ddr2-antikörper und verwendungen davon
JP2024520764A (ja)	2021-06-07	2024-05-24	アレストレーディングソシエテアノニム	癌の組み合わせ処置
EP4351582B1 (de)	2021-06-09	2025-10-08	F. Hoffmann-La Roche AG	Kombination eines bestimmten braf-inhibitors (paradoxbrecher) mit einem pd-1 achsenbindenden antagonisten zur verwendung in der krebsbehandlung
WO2022265912A1 (en)	2021-06-16	2022-12-22	Gundersen Lutheran Medical Foundation, Inc.	Antibodies targeting an amphiregulin-derived cell surface neo-epitope
CN117642426A (zh)	2021-06-16	2024-03-01	艾莱克特有限责任公司	双特异性抗MerTK和抗PDL1抗体及其使用方法
JP2024527493A (ja)	2021-06-16	2024-07-25	アレクトルエルエルシー	一価の抗ＭｅｒＴＫ抗体及びその使用方法
EP4355785A1 (de)	2021-06-17	2024-04-24	Amberstone Biosciences, Inc.	Anti-cd3-konstrukte und verwendungen davon
KR20240049265A (ko)	2021-06-18	2024-04-16	테리니 바이오, 인코포레이티드	인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법
TWI879694B (zh)	2021-06-25	2025-04-01	日商中外製藥股份有限公司	抗ctla-4抗體的用途
IL309115A (en)	2021-06-25	2024-02-01	Chugai Pharmaceutical Co Ltd	Anti-CTLA-4 antibodies
US20250312468A1 (en)	2021-07-02	2025-10-09	Merck Patent Gmbh	Anti-protac antibodies and complexes
KR20240032889A (ko)	2021-07-14	2024-03-12	제넨테크, 인크.	항-c-c 모티프 케모카인 수용체 8(ccr8) 항체 및 사용 방법
WO2023004304A1 (en)	2021-07-20	2023-01-26	Inhibrx, Inc.	Cd8-binding polypeptides and uses thereof
WO2023004305A1 (en)	2021-07-20	2023-01-26	Inhibrx, Inc.	Cd8-targeted modified il-2 polypeptides and uses thereof
AU2022315528A1 (en)	2021-07-22	2023-10-19	F. Hoffmann-La Roche Ag	Heterodimeric fc domain antibodies
WO2023004386A1 (en)	2021-07-22	2023-01-26	Genentech, Inc.	Brain targeting compositions and methods of use thereof
AU2022318255A1 (en)	2021-07-27	2024-01-18	Morphosys Ag	Combinations of antigen binding molecules
CN117813320A (zh)	2021-07-30	2024-04-02	Inserm(法国国家健康医学研究院)	嵌合蛋白和免疫治疗方法
JP2024528217A (ja)	2021-08-03	2024-07-26	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	二重特異性抗体および使用方法
WO2023019239A1 (en)	2021-08-13	2023-02-16	Genentech, Inc.	Dosing for anti-tryptase antibodies
EP4388014A1 (de)	2021-08-19	2024-06-26	F. Hoffmann-La Roche AG	Multivalente antivariante antikörper gegen fc-region und verfahren zur verwendung
IL310382A (en)	2021-08-27	2024-03-01	Genentech Inc	Methods for treating tau pathologies
TW202325727A (zh)	2021-08-30	2023-07-01	美商建南德克公司	抗聚泛素多特異性抗體
EP4396229A1 (de)	2021-09-02	2024-07-10	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Anti-cecam6-antikörper mit reduzierten nebenwirkungen
WO2023056240A2 (en)	2021-09-28	2023-04-06	Frontaim Biomedicines, Inc.	Multiple formats of molecular complexes
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
WO2023056403A1 (en)	2021-09-30	2023-04-06	Genentech, Inc.	Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
US20240404622A1 (en)	2021-10-08	2024-12-05	Chugai Seiyaku Kabushiki Kaisha	Method for preparing prefilled syringe formulation
JP2024537096A (ja)	2021-10-14	2024-10-10	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がんの治療のための代替的なＰＤ１－ＩＬ７ｖイムノコンジュゲート
CR20240155A (es)	2021-10-14	2024-05-10	Hoffmann La Roche	Nuevos inmunoconjugados de interleucina-7
EP4419558A1 (de)	2021-10-19	2024-08-28	Alector LLC	Anti-cd300lb-antikörper und verfahren zur verwendung davon
US20240426823A1 (en)	2021-11-03	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023081898A1 (en)	2021-11-08	2023-05-11	Alector Llc	Soluble cd33 as a biomarker for anti-cd33 efficacy
JP2024544885A (ja)	2021-11-10	2024-12-05	ジェネンテック，インコーポレイテッド	抗インターロイキン－３３抗体及びその使用
WO2023091887A1 (en)	2021-11-16	2023-05-25	Genentech, Inc.	Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
EP4437006A1 (de)	2021-11-26	2024-10-02	F. Hoffmann-La Roche AG	Kombinationstherapie von bispezifischen anti-tyrp1/anti-cd3-antikörpern und tyrp1-spezifischen antikörpern
AU2022399314A1 (en)	2021-12-01	2024-06-20	Chugai Seiyaku Kabushiki Kaisha	Method for preparing antibody-containing formulation
AR127887A1 (es)	2021-12-10	2024-03-06	Hoffmann La Roche	Anticuerpos que se unen a cd3 y plap
KR20240116755A (ko)	2021-12-17	2024-07-30	상하이 헨리우스 바이오테크, 인크.	항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
AU2022411573A1 (en)	2021-12-17	2024-06-27	Shanghai Henlius Biologics Co., Ltd.	Anti-ox40 antibodies and methods of use
WO2023118165A1 (en)	2021-12-21	2023-06-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and compositions for treating melanoma
CN118176020A (zh)	2021-12-23	2024-06-11	江苏恒瑞医药股份有限公司	抗dll3抗体、其抗体-药物偶联物及其医药用途
AU2023205911A1 (en)	2022-01-05	2024-07-11	Inhibrx Biosciences, Inc.	Gamma delta t-cell-binding polypeptides and uses thereof
WO2023133393A1 (en)	2022-01-05	2023-07-13	Inhibrx, Inc.	Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
WO2023141445A1 (en)	2022-01-19	2023-07-27	Genentech, Inc.	Anti-notch2 antibodies and conjugates and methods of use
AR128330A1 (es)	2022-01-26	2024-04-17	Genentech Inc	Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es)	2022-01-26	2024-04-17	Genentech Inc	Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
WO2023144235A1 (en)	2022-01-27	2023-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
WO2023144973A1 (ja)	2022-01-27	2023-08-03	中外製薬株式会社	抗ｖｅｇｆ抗体及びパクリタキセルと組み合わせて使用する抗ｐｄ－ｌ１抗体を含む医薬組成物
EP4469159A1 (de)	2022-01-27	2024-12-04	The Rockefeller University	Breit neutralisierende anti-sars-cov-2-antikörper gegen die n-terminale domäne des spike-proteins und verfahren zur verwendung davon
WO2023164516A1 (en)	2022-02-23	2023-08-31	Alector Llc	Methods of use of anti-trem2 antibodies
EP4489790A1 (de)	2022-03-10	2025-01-15	Vivasor, Inc.	Antikörper-wirkstoff-konjugate und verwendungen davon
CR20240375A (es)	2022-03-11	2025-01-06	Mablink Bioscience	Conjugados anticuerpo-fármaco y sus usos
WO2023180353A1 (en)	2022-03-23	2023-09-28	F. Hoffmann-La Roche Ag	Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
JP2025514610A (ja)	2022-03-25	2025-05-09	シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド	抗ｍｓｌｎ抗体及び使用方法
AR128876A1 (es)	2022-03-28	2024-06-19	Hoffmann La Roche	Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
AU2022450448A1 (en)	2022-04-01	2024-10-10	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
CN116925223A (zh)	2022-04-02	2023-10-24	普米斯生物技术(珠海)有限公司	抗pd-1单克隆抗体及其衍生物和用途
CA3247628A1 (en)	2022-04-08	2023-10-12	Inhibrx Biosciences, Inc.	POLYTHERAPY INCLUDING A DR5 AGONIST AND A PLK1 OR CDK INHIBITOR
TW202404637A (zh)	2022-04-13	2024-02-01	瑞士商赫孚孟拉羅股份公司	抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
US20230406930A1 (en)	2022-04-13	2023-12-21	Genentech, Inc.	Pharmaceutical compositions of therapeutic proteins and methods of use
IL316445A (en)	2022-04-26	2024-12-01	Chugai Pharmaceutical Co Ltd	A syringe containing a pharmaceutical preparation equipped with a filter
WO2023212675A1 (en)	2022-04-28	2023-11-02	Allogene Therapeutics Inc.	Methods for donor cell analysis
JP2025514437A (ja)	2022-04-29	2025-05-02	ブロードウィングバイオリミテッドライアビリティカンパニー	二重特異性抗体及び眼疾患の処置方法
IL316289A (en)	2022-04-29	2024-12-01	Purinomia Biotech Inc	Methods and compositions for treating diseases and disorders driven by eosinophils
IL316610A (en)	2022-04-29	2024-12-01	Broadwing Bio Llc	4-specific antibodies related to complement factor H and uses thereof
US20250296996A1 (en)	2022-04-29	2025-09-25	Broadwing Bio, Inc.	Angiopoietin-related protein 7-specific antibodies and uses thereof
WO2023213814A1 (en)	2022-05-02	2023-11-09	Pierre Fabre Medicament	New formulation of anti vista antibody
TW202406934A (zh)	2022-05-03	2024-02-16	美商建南德克公司	抗Ｌｙ６Ｅ抗體、免疫結合物及其用途
EP4519311A1 (de)	2022-05-05	2025-03-12	Inhibrx Biosciences, Inc.	Albuminbindende polypeptide und verwendungen davon
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023275703A1 (en)	2022-05-23	2024-11-21	Inhibrx Biosciences, Inc.	Dr5 agonist and iap antagonist combination therapy
WO2023235699A1 (en)	2022-05-31	2023-12-07	Jounce Therapeutics, Inc.	Antibodies to lilrb4 and uses thereof
WO2023235415A1 (en)	2022-06-01	2023-12-07	Genentech, Inc.	Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
CA3257760A1 (en)	2022-06-07	2023-12-14	Genentech, Inc.	PROGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
EP4536290A1 (de)	2022-06-08	2025-04-16	Angiex, Inc.	Anti-tm4sf1-antikörper-wirkstoff-konjugate mit spaltbaren linkern und verfahren zur verwendung davon
EP4536853A1 (de)	2022-06-09	2025-04-16	Allogene Therapeutics, Inc.	Verfahren zur erkennung genomischer anomalien in zellen
EP4536198A1 (de)	2022-06-09	2025-04-16	Institut National de la Santé et de la Recherche Médicale	Verwendung von endothelinrezeptor-typ-b-agonisten zur behandlung von aortenklappenstenose
WO2023240216A1 (en)	2022-06-11	2023-12-14	Inhibrx, Inc.	Fcrn-binding polypeptides and uses thereof
CN120187452A (zh)	2022-06-13	2025-06-20	基因泰克公司	使用克瑞尼珠单抗延迟或预防阿尔茨海默病的发作的方法
JP2025521677A (ja)	2022-07-06	2025-07-10	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	増殖性糸球体腎炎を処置するための方法
WO2024013234A1 (en)	2022-07-13	2024-01-18	Institut National de la Santé et de la Recherche Médicale	Methods for diagnosis, prognosis, stratification and treating of myocarditis
WO2024015897A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2023309556A1 (en)	2022-07-19	2025-01-23	F. Hoffmann-La Roche Ag	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020564A1 (en)	2022-07-22	2024-01-25	Genentech, Inc.	Anti-steap1 antigen-binding molecules and uses thereof
WO2024020579A1 (en)	2022-07-22	2024-01-25	Bristol-Myers Squibb Company	Antibodies binding to human pad4 and uses thereof
AU2023314807A1 (en)	2022-07-29	2025-03-06	Alector Llc	Transferrin receptor antigen-binding domains and uses therefor
AU2023316021A1 (en)	2022-07-29	2025-03-06	Alector Llc	Cd98hc antigen-binding domains and uses therefor
WO2024026447A1 (en)	2022-07-29	2024-02-01	Alector Llc	Anti-gpnmb antibodies and methods of use thereof
WO2024028433A1 (en)	2022-08-04	2024-02-08	Institut National de la Santé et de la Recherche Médicale	Methods for the treatment of lymphoproliferative disorders
WO2024033399A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en)	2022-08-10	2024-02-15	Institut National de la Santé et de la Recherche Médicale	Sk2 inhibitor for the treatment of pancreatic cancer
WO2024040090A1 (en)	2022-08-16	2024-02-22	Allogene Therapeutics Inc.	In vitro method for inhibiting hhv-6 infection
AR130241A1 (es)	2022-08-18	2024-11-20	Immunocore Ltd	Receptores de linfocitos t y proteínas de fusión de estos
JP2025531738A (ja)	2022-09-01	2025-09-25	ジェネンテック，インコーポレイテッド	膀胱がんの治療方法及び診断方法
US20260078185A1 (en)	2022-09-07	2026-03-19	Dynamicure Biotechnology Llc	Anti-vista constructs and uses thereof
KR20250059447A (ko)	2022-09-08	2025-05-02	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	항-ilt4 항체 및 이의 의약적 용도
JP2025533570A (ja)	2022-09-28	2025-10-07	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	改良されたプロテアーゼ活性化型ｔ細胞二重特異性抗体
CN119948048A (zh)	2022-09-29	2025-05-06	豪夫迈·罗氏有限公司	蛋白酶活化的多肽
IL319943A (en)	2022-10-07	2025-05-01	Genentech Inc	Methods for treating cancer with anti-C motif chemokine receptor 8 (CCR8) antibodies
WO2024086796A1 (en)	2022-10-20	2024-04-25	Alector Llc	Anti-ms4a4a antibodies with amyloid-beta therapies
WO2024084034A1 (en)	2022-10-21	2024-04-25	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical compositions for the treatment of osteoarthritis
IL320355A (en)	2022-10-25	2025-06-01	Genentech Inc	Therapeutic and diagnostic methods for multiple myeloma
CN120051301A (zh)	2022-11-04	2025-05-27	吉利德科学公司	使用抗ccr8抗体、化学疗法和免疫疗法组合的抗癌疗法
WO2024102734A1 (en)	2022-11-08	2024-05-16	Genentech, Inc.	Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
WO2024100170A1 (en)	2022-11-11	2024-05-16	F. Hoffmann-La Roche Ag	Antibodies binding to hla-a*02/foxp3
AU2023379743A1 (en)	2022-11-17	2025-07-03	Sanofi	Ceacam5 antibody-drug conjugates and methods of use thereof
TW202440623A (zh)	2022-11-28	2024-10-16	美商艾洛基因醫療公司	靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
JP2025528316A (ja)	2022-12-08	2025-08-28	ナンジン、バザイム、バイオテック、カンパニー、リミテッド	Ｒｓｖに特異的に結合する抗体
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
EP4634397A1 (de)	2022-12-12	2025-10-22	Genentech Inc.	Optimierung des sialinsäuregehalts von polypeptiden
AU2023408612A1 (en)	2022-12-20	2025-07-03	BioNTech SE	Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024133723A1 (en)	2022-12-22	2024-06-27	Institut National de la Santé et de la Recherche Médicale	Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
IL321713A (en)	2022-12-27	2025-08-01	Merck Patent Gmbh	Anti-PROTAC VHH antibodies and complexes
WO2024145398A1 (en)	2022-12-27	2024-07-04	Yale University	Antibody drug conjugates
IL324586A (en)	2022-12-30	2026-01-01	Remegen Shanghai Co Ltd	Bispecific antibody and its use
JP2026503002A (ja)	2023-01-06	2026-01-27	アレクトルエルエルシー	抗ｉｌ１８結合タンパク質抗体及びその使用方法
PE20252286A1 (es)	2023-01-18	2025-09-18	Genentech Inc	Anticuerpos multiespecificos y usos de estos
KR20250135861A (ko)	2023-01-20	2025-09-15	에프. 호프만-라 로슈 아게	재조합 Fc 도메인 - IL2 변이체 폴리펩타이드 및 막 고정 항원 결합 폴리펩타이드와의 조합 요법
EP4655007A1 (de)	2023-01-23	2025-12-03	Yale University	Antikörper-oligonukleotid-konjugate
JP2026505747A (ja)	2023-01-25	2026-02-18	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	Ｃｓｆ１ｒおよびｃｄ３に結合する抗体
JP2026508154A (ja)	2023-02-27	2026-03-10	スゥジョウサンカディアバイオファーマシューティカルズカンパニーリミテッド	抗ｄｌｌ３抗体、その抗体－薬物複合体及びその医薬的使用
WO2024191785A1 (en)	2023-03-10	2024-09-19	Genentech, Inc.	Fusions with proteases and uses thereof
JP2026508657A (ja)	2023-03-16	2026-03-11	アイタブメッドカンパニー，リミテッド	多重特異性抗原結合タンパク質及びその使用
WO2024197302A1 (en)	2023-03-23	2024-09-26	Yale University	Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
AU2024248331A1 (en)	2023-03-31	2025-10-09	Genentech, Inc.	Anti-alpha v beta 8 integrin antibodies and methods of use
WO2024206738A1 (en)	2023-03-31	2024-10-03	Immunai Inc.	Humanized anti-trem2 antibodies
WO2024211234A1 (en)	2023-04-05	2024-10-10	Sorrento Therapeutics, Inc.	Antibody-drug conjugates and uses thereof
EP4687997A2 (de)	2023-04-05	2026-02-11	Sorrento Therapeutics, Inc.	Antikörper-wirkstoff-konjugate und verwendungen davon
EP4687995A1 (de)	2023-04-05	2026-02-11	Sorrento Therapeutics, Inc.	Antikörper-wirkstoff-konjugate und verwendungen davon
KR20250169602A (ko)	2023-04-13	2025-12-03	지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드	Egfr 및 muc1에 특이적으로 결합하는 항원 결합 분자, 이의 약물 접합체 및 이의 의약적 용도
EP4695287A1 (de)	2023-04-14	2026-02-18	Twist Bioscience Corporation	Zusammensetzungen und verfahren im zusammenhang mit dkk1-bindemitteln
EP4696321A1 (de)	2023-04-14	2026-02-18	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur stabilisierung einer proteinhaltigen pharmazeutischen zubereitung
CN121263210A (zh)	2023-04-17	2026-01-02	沛科生物公司	抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
CN121311765A (zh)	2023-04-18	2026-01-09	朱诺治疗学股份有限公司	评估治疗性细胞组合物的效力的细胞毒性测定
WO2024227154A1 (en)	2023-04-28	2024-10-31	Broadwing Bio Llc	Complement component 3 (c3)-specific antibodies and uses thereof
WO2024233341A1 (en)	2023-05-05	2024-11-14	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
AU2024269754A1 (en)	2023-05-08	2025-10-23	F. Hoffmann-La Roche Ag	Targeted interferon alpha fusion proteins and methods of use
KR20260008790A (ko)	2023-05-10	2026-01-16	제넨테크, 인크.	암 치료 방법 및 조성물
WO2024238537A1 (en)	2023-05-16	2024-11-21	F. Hoffmann-La Roche Ag	Pd-1 -regulated il-2 immunocytokine and uses thereof
CN121604979A (zh)	2023-05-23	2026-03-03	上海联进生物科技有限公司	包含效应分子的pd-l1和trop-2靶向缀合物及其用途
WO2024245951A1 (en)	2023-05-26	2024-12-05	Institut National de la Santé et de la Recherche Médicale	Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
TW202448933A (zh)	2023-05-31	2024-12-16	美商建南德克公司	用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
WO2024246086A1 (en)	2023-06-01	2024-12-05	F. Hoffmann-La Roche Ag	Immunostimulatory antigen binding molecules that specifically bind to bcma
CN121241068A (zh)	2023-06-01	2025-12-30	豪夫迈·罗氏有限公司	靶向bcma和cd28的双特异性抗体
AU2024287056A1 (en)	2023-06-08	2025-12-11	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-npr1 antibody and pharmaceutical use thereof
IL324958A (en)	2023-06-08	2026-01-01	Genentech Inc	Macrophage signatures for diagnostic and therapeutic approaches for lymphoma
EP4477236A1 (de)	2023-06-14	2024-12-18	Inatherys	Kombinationstherapie zur behandlung eines tumors mit adc mit anti-cd71-antikörpern und bh3-mimetika
WO2024256635A1 (en)	2023-06-15	2024-12-19	Institut National de la Santé et de la Recherche Médicale	Dpm1 inhibitor for treating cancer
KR20260025162A (ko)	2023-06-20	2026-02-23	알로젠 테라퓨틱스 인코포레이티드	조작된 세포의 검출 방법
WO2024261302A1 (en)	2023-06-22	2024-12-26	Institut National de la Santé et de la Recherche Médicale	Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2024263761A1 (en)	2023-06-22	2024-12-26	Genentech, Inc.	Antibodies and uses thereof
CN121443309A (zh)	2023-06-22	2026-01-30	基因泰克公司	多发性骨髓瘤的治疗
WO2025003511A1 (en)	2023-06-30	2025-01-02	Morphosys Ag	Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025024265A1 (en)	2023-07-21	2025-01-30	Bristol-Myers Squibb Company	Methods of assessing citrullination and activity of pad4 modulators
AU2024300060A1 (en)	2023-07-25	2026-03-12	Merck Patent Gmbh	Iduronidase-cleavable compounds
WO2025021838A1 (en)	2023-07-26	2025-01-30	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
WO2025034806A1 (en)	2023-08-08	2025-02-13	Wisconsin Alumni Research Foundation	Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025032069A1 (en)	2023-08-09	2025-02-13	F. Hoffmann-La Roche Ag	Mono and multispecific anti-trem2 antibodies, methods and uses thereof
CN121666400A (zh)	2023-08-09	2026-03-13	豪夫迈·罗氏有限公司	单特异性和多特异性抗trem2抗体、其方法和用途
WO2025036892A1 (en)	2023-08-14	2025-02-20	Morphosys Ag	Cycat halfbody molecules comprising sterically occluding moieties
WO2025038668A1 (en)	2023-08-14	2025-02-20	Voro Therapeutics, Inc.	Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025038893A2 (en)	2023-08-16	2025-02-20	University Of Tennessee Research Foundation	Methods of inhibiting fibril growth
WO2025049343A1 (en)	2023-08-25	2025-03-06	Proteologix Us Inc.	Anti-tslp antibody constructs and uses thereof
WO2025049345A1 (en)	2023-08-25	2025-03-06	Proteologix Us Inc.	Anti-il-13 multispecific antibody constructs and uses thereof
WO2025049905A1 (en)	2023-09-01	2025-03-06	Gennao Bio, Inc.	Dnase co-expression in host cells
WO2025048860A1 (en)	2023-09-01	2025-03-06	Inhibrx Biosciences, Inc.	Ox40 agonist therapy
WO2025048887A1 (en)	2023-09-01	2025-03-06	Inhibrx Biosciences, Inc.	Ox40 agonist therapy
WO2025045250A1 (en)	2023-09-03	2025-03-06	Kira Pharmaceuticals (Us) Llc	Anti-human factor d antibody constructs and uses thereof
TW202525856A (zh)	2023-09-08	2025-07-01	美商Ｍｌａｂ生物科學有限公司	雙功能性蛋白質及其用途
AR133909A1 (es)	2023-09-25	2025-11-12	Hoffmann La Roche	ANTICUERPO QUE SE UNE A C3bBb
US12122842B1 (en)	2023-09-27	2024-10-22	R&D Systems, Inc.	Human CD30-specific binding proteins and uses thereof
WO2025078632A1 (en)	2023-10-12	2025-04-17	Institut National de la Santé et de la Recherche Médicale	Methods of prognosis and treatment of patients suffering from cancer
WO2025082777A1 (en)	2023-10-17	2025-04-24	Morphosys Ag	Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025085489A1 (en)	2023-10-17	2025-04-24	Bristol-Myers Squibb Company	Gspt1-degrading compounds, anti-cd33 antibodies and antibody-drug conjugates and uses thereof
WO2025087681A1 (en)	2023-10-26	2025-05-01	Morphosys Ag	Bispecific antibodies against cd3 and cd20
WO2025106474A1 (en)	2023-11-14	2025-05-22	Genentech, Inc.	Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025106634A1 (en)	2023-11-17	2025-05-22	Genentech, Inc.	Mcl-1 inhibitor compounds and use in antibody drug conjugates
AR134514A1 (es)	2023-12-01	2026-01-21	Gilead Sciences Inc	Proteína de fusión anti-fap-ligera y uso de esta
WO2025117848A1 (en)	2023-12-01	2025-06-05	Genentech, Inc.	Low-viscosity variants of antibodies
WO2025129010A1 (en)	2023-12-14	2025-06-19	Genentech, Inc.	Methods of structure determination using antibodies
WO2025132479A1 (en)	2023-12-18	2025-06-26	Institut National de la Santé et de la Recherche Médicale	Flt3 inhibitor for modulating macrophages polarization
US20260071002A1 (en)	2023-12-20	2026-03-12	Hoffmann-La Roche Inc.	Antibodies binding to ceacam5
WO2025137086A1 (en)	2023-12-20	2025-06-26	Genentech, Inc.	Reducing alpha-gal
TW202542177A (zh)	2023-12-22	2025-11-01	瑞士商赫孚孟拉羅股份公司	可活化融合蛋白及使用方法
WO2025155602A1 (en)	2024-01-16	2025-07-24	Genentech, Inc.	Method of treating hemophilia a
TW202539700A (zh)	2024-01-16	2025-10-16	美商建南德克公司	用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療泌尿上皮癌之方法
WO2025153608A1 (en)	2024-01-18	2025-07-24	Institut National de la Santé et de la Recherche Médicale	Wip1 inhibitor for the treatment of glomerular disease
WO2025166040A1 (en)	2024-01-31	2025-08-07	Alector Llc	Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166077A1 (en)	2024-01-31	2025-08-07	Alector Llc	Compositions comprising progranulin and uses thereof
WO2025166042A1 (en)	2024-01-31	2025-08-07	Alector Llc	Cd98hc antigen-binding domains and uses therefor
WO2025166045A1 (en)	2024-01-31	2025-08-07	Alector Llc	β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025174974A1 (en)	2024-02-14	2025-08-21	Bristol-Myers Squibb Company	Anti-cd33 antibodies and uses thereof
WO2025176614A1 (en)	2024-02-20	2025-08-28	F. Hoffmann-La Roche Ag	Novel pre-targeting antibodies and uses thereof
WO2025178959A1 (en)	2024-02-20	2025-08-28	University Of Georgia Research Foundation, Inc.	Single-domain antibodies and variants thereof against tab1
WO2025181189A1 (en)	2024-03-01	2025-09-04	F. Hoffmann-La Roche Ag	Antibodies binding to cd3
US20250295801A1 (en)	2024-03-21	2025-09-25	Seagen Inc.	Cd25 antibodies, antibody drug conjugates, and uses thereof
WO2025202147A1 (en)	2024-03-27	2025-10-02	F. Hoffmann-La Roche Ag	Interleukin-7 immunoconjugates
WO2025210123A1 (en)	2024-04-03	2025-10-09	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for treating cancers
WO2025215060A1 (en)	2024-04-11	2025-10-16	F. Hoffmann-La Roche Ag	Antibodies that specifically bind modified oligonucleotides
US12509510B2 (en)	2024-04-23	2025-12-30	Attovia Therapeutics, Inc.	IL31-binding polypeptides and uses thereof
WO2025226808A1 (en)	2024-04-24	2025-10-30	Genentech, Inc.	Compositions and methods of treating lupus nephritis
EP4643858A1 (de)	2024-04-29	2025-11-05	Institut National de la Santé et de la Recherche Médicale	Verfahren und pharmazeutische zusammensetzung zur behandlung von gebärmuttererkrankungen
WO2025228998A1 (en)	2024-04-30	2025-11-06	Institut National de la Santé et de la Recherche Médicale	Use of hdac4 inhibitors for the treatment of melanoma
WO2025233304A1 (en)	2024-05-08	2025-11-13	F. Hoffmann-La Roche Ag	Recombinant fc domain – il7 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
WO2025247829A1 (en)	2024-05-27	2025-12-04	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for treating prostate cancer
WO2025248500A1 (en)	2024-05-31	2025-12-04	Janssen Biotech, Inc.	Antibody drug conjugates that target enpp3
WO2025248102A1 (en)	2024-05-31	2025-12-04	Institut National de la Santé et de la Recherche Médicale	Tbk1 inhibitor for use in the treatment of vitiligo
US20250376536A1 (en)	2024-06-06	2025-12-11	Bristol-Myers Squibb Company	Multispecific anti-cd40 / anti-fap antibodies and uses thereof
WO2025255405A1 (en)	2024-06-06	2025-12-11	Bristol-Myers Squibb Company	Anti-fap antibodies and uses thereof
WO2025257151A1 (en)	2024-06-10	2025-12-18	Institut National de la Santé et de la Recherche Médicale	Methods and pharmaceutical composition for treating ciliopathies
US20260056209A1 (en)	2024-06-14	2026-02-26	Gilead Sciences, Inc.	Anti-ccr8 antibodies and uses thereof
WO2025264572A1 (en)	2024-06-17	2025-12-26	Alector Llc	Transferrin receptor antigen-binding domains and uses therefor
WO2026006162A2 (en)	2024-06-24	2026-01-02	Genentech, Inc.	B vitamin modulation
WO2026012976A1 (en)	2024-07-08	2026-01-15	Institut National de la Santé et de la Recherche Médicale	Use of inhibitor of gasdermind for treatment of rac2 monogenic disorders
WO2026013071A1 (en)	2024-07-09	2026-01-15	Institut National de la Santé et de la Recherche Médicale	Setdb1 inhibitor for use in the treatment of uveal melanoma
US20260078179A1 (en)	2024-07-18	2026-03-19	Novarock Biotherapeutics, Ltd.	Cdh17 antibodies and uses thereof
WO2026030464A1 (en)	2024-07-30	2026-02-05	Genentech, Inc.	Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
WO2026041568A1 (en)	2024-08-20	2026-02-26	F. Hoffmann-La Roche Ag	Antibodies binding to cd3 and dotam
WO2026055143A2 (en)	2024-09-03	2026-03-12	Attovia Therapeutics, Inc.	Il13-binding polypeptides and uses thereof
WO2026055142A1 (en)	2024-09-03	2026-03-12	Attovia Therapeutics, Inc.	Il13 and il31 bispecific polypeptides and uses thereof
WO2026055521A1 (en)	2024-09-06	2026-03-12	University Of Tennessee Research Foundation	Antibody-peptide fusion proteins for treating amyloid disorders
WO2026057679A1 (en)	2024-09-11	2026-03-19	Institut National de la Santé et de la Recherche Médicale	Inhibitor of rab30 for use in a method of treatment of metabolic dysfunction-associated steatotic liver disease (masld)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5565332A (en) *	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en)	1991-12-06	1992-02-05	Wellcome Found	Antibody

1998
- 1998-12-04 AT AT98960758T patent/ATE531812T1/de active
- 1998-12-04 AU AU16280/99A patent/AU760562B2/en not_active Ceased
- 1998-12-04 BR BR9813365-9A patent/BR9813365A/pt active Search and Examination
- 1998-12-04 PT PT98960758T patent/PT1034298E/pt unknown
- 1998-12-04 DK DK98960758.5T patent/DK1034298T3/da active
- 1998-12-04 EP EP98960758A patent/EP1034298B1/de not_active Expired - Lifetime
- 1998-12-04 CA CA2312208A patent/CA2312208C/en not_active Expired - Fee Related
- 1998-12-04 JP JP2000524459A patent/JP4460155B2/ja not_active Expired - Fee Related
- 1998-12-04 WO PCT/US1998/025828 patent/WO1999029888A1/en not_active Ceased
- 1998-12-04 IL IL13654498A patent/IL136544A0/xx active IP Right Grant
- 1998-12-04 ES ES98960758T patent/ES2375931T3/es not_active Expired - Lifetime
2000
- 2000-06-04 IL IL136544A patent/IL136544A/en not_active IP Right Cessation
2002
- 2002-02-19 US US10/078,757 patent/US7087409B2/en not_active Expired - Lifetime
2012
- 2012-01-17 CY CY20121100047T patent/CY1112365T1/el unknown

Also Published As

Publication number	Publication date
AU1628099A (en)	1999-06-28
IL136544A (en)	2007-07-24
US20030166871A1 (en)	2003-09-04
CA2312208A1 (en)	1999-06-17
AU760562B2 (en)	2003-05-15
CY1112365T1 (el)	2015-12-09
IL136544A0 (en)	2001-06-14
DK1034298T3 (da)	2012-01-30
PT1034298E (pt)	2012-02-03
US7087409B2 (en)	2006-08-08
BR9813365A (pt)	2004-06-15
EP1034298A1 (de)	2000-09-13
EP1034298B1 (de)	2011-11-02
JP2001526044A (ja)	2001-12-18
JP4460155B2 (ja)	2010-05-12
EP1034298A4 (de)	2005-01-19
WO1999029888A1 (en)	1999-06-17
CA2312208C (en)	2011-01-25
ES2375931T3 (es)	2012-03-07

Publication	Publication Date	Title
ATE531812T1 (de)	2011-11-15	Humanisierung von nager-antikörpern
CA2469833A1 (en)	2003-07-24	Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
PT804237E (pt)	2006-10-31	Anticorpos humanizados contra a molecula de adesao leucocitaria vla-4
CY1121451T1 (el)	2020-05-29	Ανθρωπινα μονοκλωνικα αντισωματα κατα του ctla-4
DK0979246T3 (da)	2007-11-05	Humane monoklonale antistoffer mod epidermal vækstfaktorreceptor
PT699237E (pt)	2003-07-31	Fvs de cadeia anti-egfr e anticorpos anti-egfr
NO20063224L (no)	2006-07-11	Anti-MPL-antistoff
KR950700414A (ko)	1995-01-16	사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
DE50115580D1 (de)	2010-09-16	Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
EP2067788A3 (de)	2010-04-21	FAB-Fragmentbibliotheken und Verwendungsverfahren dafür
ATE509955T1 (de)	2011-06-15	Humanisierte kollagen-antikörper und damit verbundene verfahren
DE69828154D1 (de)	2005-01-20	Anti-alphavbeta3 humanizierte monoklonale antikörper
DE60238987D1 (de)	2011-03-03	Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
DE69615843D1 (de)	2001-11-15	Il-8 antagonisten zur behandlung von asthma
ATE315048T1 (de)	2006-02-15	Monoklonaler antikoerper spezifisch fuer prostaglandin d synthetase
EP1396539A4 (de)	2004-07-28	Humanantikörper gegen blutgerinnungsfaktor viii
ATE208403T1 (de)	2001-11-15	Antiidiotypische antikörper die eine immunantwort gegen den rezeptor für epidermalen wachstumsfaktor induzieren
ATE309371T1 (de)	2005-11-15	Protein mit dnase-aktivität
BR1100555B1 (pt)	2009-01-13	anticorpos monoclonais humanizados.
HUP9903273A3 (en)	2000-03-28	Anti-human mp52 monoclonal antibody